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To rapidly detect early stage infections the innate immune system maintains an
assortment of pathogen recognition mechanisms interspersed throughout both the
extracellular and intracellular environments. These sensors recognize key components
of viral, bacterial and fungal pathogens, and stimulate an inflammatory response which
leads to the expression of an extensive network of host defense proteins. One such
canonical network is regulated by type I interferon. This pathway responds to viral
infections by upregulating hundreds of interferon stimulated genes (ISG) critical for host
immunity.
One of the more pivotal proteins for viral control is interferon-induced
transmembrane protein 3 (IFITM3). IFITM3 is a host protein known to play a key role in
inhibiting numerous virus infections, including influenza, Dengue, West Nile, HIV and
Ebola. It is active in the early stages of infection and interferes with viral fusion and
content delivery to the cell cytoplasm. Despite this broad antiviral activity, the exact
mechanism of IFITM3 viral fusion interference, and whether it directly interacts with the
fusion environment remains unknown.
To better understand the physiological conditions of IFITM3 antiviral activity, we
required an improved understanding of the endogenous levels of S-fatty acylation.
While earlier work in our lab has shown this post-translational modification to be critical

for IFITM3 activity, it was previously impossible to distinguish between different modified
populations. I therefore developed the acyl PEG exchange (APE) assay. Utilizing
cysteine selective mass tags, APE detects different levels of fatty acylated cysteines
within a protein population, which allows us to probe the lipidated states of endogenous
proteins for the first time. Using this assay, I have shown that the majority of
endogenous human IFITM3 is dually S-fatty acylated.
To investigate the mechanism of IFITM3 antiviral activity, I generated
recombinant, native, synthetically lipidated protein for structural and fusion-based
studies. We applied an in vitro viral fusion model that detects the lipid mixing of viral
envelopes with liposomes. We demonstrate that viral fusion is mitigated with the
inclusion of recombinant IFITM3 liposomes. Furthermore, when IFITM3 is modified with
maleimide palmitate to mimic fatty-acylation at cysteine 105, lipid mixing is inhibited
more than the unmodified IFITM3.
Overall, our recombinant model of viral fusion provides an in vitro approach to
investigate IFITM3 function. The assay provides the first evidence that IFITM3 directly
alters the membrane fusion environment, and that cysteine palmitoylation enhances
protein function as well. In the future, these studies will be complemented with more
accurate in vitro assays to further elucidate its critical mechanism.
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Chapter 1: Introduction
IFN-Induced Innate Immunity
The interplay and kinetics of pathogenic infections necessitates persistent, basal level
cell surveillance and rapid early response capabilities. The broadly conserved first line
of defense, the innate immune system, is a non-adaptive response triggered by
commonly conserved, pan-pathogen motifs (pathogen-associated molecular patterns,
PAMP). These bind to pathogen recognition receptors (PRRs) to activate the secretion
of inflammatory cytokines 1, which in turn upregulate a broad range of defense proteins
in immune and non-immune cells alike that disrupt pathogenicity and infection. The
innate inflammatory response is critical for orchestrating changes in gene expression 2
that provide a crucial line of defense for early stage infection, and facilitates the
development of the adaptive immune response as well3. Despite adaptive immunity
being critical for late stage infection and clearance intracellular defense mechanisms
contain no adaptive capabilities, rendering the innate response the key means of
disrupting intracellular pathogen infection.
One of the canonical inflammatory pathways is that of the interferon (IFN)
cytokines, which play a critical role in innate defense4. Mediated through the JAK/STAT
pathway (Fig.1), activation results in the upregulation of hundreds of interferonstimulated genes (ISG) that alter the cellular and tissue environment as well as detect
and combat viral replication, entry, and cell-to-cell dissemination5. IFNs are classified
into three different types – type I IFN (IFNα and IFNβ)4 type II (IFNγ)6, and type III
(IFNλ)7. While type I activation is considered the primary pathway for ISG activation,
increasing evidence is emerging for type III activation in a tissue-specific manner7,

1

suggesting a more tightly regulated and temporally controlled expression of ISG antiviral
activity.

Figure 1. Type I interferon activation pathway. From Mcnab et al. Nat Rev Immunol.
(2015)4. IFN expression is activated with the detection of PAMPs by a variety of PRRs
located in the cytoplasm, at the plasma membrane, and the endosomal lumen. Binding
of secreted IFN with receptors results in the upregulation of hundreds of different ISGs,
priming nearby cells to express antiviral proteins.

Interferon-Induced Transmembrane Protein 3:
Within the broad group of interferon-stimulated genes (ISG), members of the interferoninduced transmembrane protein (IFITM) family have emerged as potent restrictors of
viral infection. Detected as an antiviral protein from a siRNA genomic screen searching
for host factors critical for influenza A virus (IAV) infection 8, IFITM3 is an essential host
factor for viral innate defense, restricting a panoply of viruses 9 entering through the
endosomal pathway, in particular IAV10. As the IFITM family is the first ISG known to
interfere with viral infection during fusion and content entry, considerable interest has
emerged in understanding their characterization and mechanism.

2

IFITM orthologues are widely conserved among vertebrates11, with the human
IFITM family having emerged during primate evolution 12. Human IFITMs include IFITM
1, 2, 3, 5, and 10, though only IFITM1, 2, and 3 exhibit antiviral activity. IFITM10 has a
yet unknown function. IFITM3 predates the divergence of IFITM1, and IFITM2, which is
only found in gorillas, chimpanzees, and humans. Sequencing alignment of IFITM1 ,2, 3
shows similar size and domain conservation, except for IFITM1 which has lost its Nterminal domain (Fig. 2). Both our lab and others13,14 have shown IFITM2 and 3 to
contain an N-terminal YEML sorting motif that results in IFITM2 and 3 trafficking via the
plasma membrane into the endosomal pathway. IFITM1, which has lost this motif in its
N-terminus, is thought to localize to the plasma membrane.

A

B
IFITM1
IFITM2
IFITM3

---------------------MHKEEHEVAVLGPPPSTILPRSTVINIHSETSVPDHVVW 39
MNHIVQ-TFSPVNSGQPPNYEMLKEEQEVAMLGVPHNPAPPMSTVIHIRSETSVPDHVVW 59
MNHTVQTFFSPVNSGQPPNYEMLKEEHEVAVLGAPHNPAPPTSTVIHIRSETSVPDHVVW 60
* ***:***:** * . * ****:*:***********

IFITM1
SLFNTLFLNWCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGILMTIG 99
IFITM2
SLFNTLFMNTCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGIFMTIL 119
IFITM3
SLFNTLFMNPCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGILMTIL 120
*******:* *********************************************:***
IFITM1
IFITM2
IFITM3

FILLLVFGSVTVYHIMLQIIQEKRGY
LIIIPVLVVQA-QR------------ 132
LIVIPVLIFQA-YG-----------133

125

Figure 2. IFITM family evolution and IFITM1-3 sequence alignment. (A) Modified
gain/loss phylogenetic tree from Compton et al. EMBO reports (2016)12. Asterisk marks
evolutionary appearance of IFITM2. (B) Sequence alignment of human IFITM1, 2 and 3.
Aligned using Clustal Omega.
3

IFITM3 membrane topology is a critical factor in exploring possible interactions
and mechanisms of interference. Earlier work in our lab using cytoplasmic lipidation
motif reporters15, and work by others showing the association of IFITM3 with μ2 AP-2
proteins14 and flow cytometry-based surface labeling16 provide strong evidence that the
N-terminal domain is cytoplasmic facing. In contrast, conflicting reports of the C-terminal
topology leave it unclear whether it contains a transmembrane, or amphipathic domain
13,16.

Recent EPR and NMR data of recombinant protein indicates IFITM3 contains one

transmembrane domain (therefore a type II membrane protein) 17, though this data was
obtained with DPC micelles (not a lipid bilayer), and with protein that was denatured
during purification(Fig. 3). While promising, additional studies will be necessary to
confirm the exact topology in the appropriate environment.

B

A

Figure 3. Membrane topology of IFITM3. (A) NMR/EPR predicted topology and (B)
respective model of IFITM3, proposed by Ling et al. Science Reports, 2016 17.
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Broad antiviral activity makes IFITM3 a critical first line of innate immune defense.
Since the first reports on IFITM3 antiviral activity against IAV and Dengue8, a
considerable body of work has emerged elucidating the range of viruses susceptible to
inhibition. This research has shown IFITM3 to be active against most clinically relevant
viral pathogens (Table 1). It has also established the importance of IFITM3 in different
tissues such as the lung18, liver19 and spleen20, and diverse cell types, including
epithelial cells18, fibroblasts21, dendritic cells22, and CD8+ T cells23.

Table 1. Antiviral activity of IFITM family. Updated table from Smith et al. 9: ‘X’, viral
entry fusion independent. ɸ, viral entry requires lysosomal cathepsins for priming and
entry.
Family

Orthomyxoviridae

Flaviviridae

Rhabdoviridae

Filoviridae

Virus

Fusion pH
Conditions

Restricted
by IFITMs

Active IFITM

Reference

Influenza A virus

< pH 6

✔

2,3

8, 28,61

Influenza B virus

<pH 6

✔

1-3

74

West Nile virus

pH >6

✔

1-3

8, 21

Zika Virus

<pH 6

✔

3

24

Dengue virus

<pH 6

✔

1-3

8

Hepatitis C virus

pH >6

✔

1-3

8, 19,25

Vesicular stomatitis
virus

pH >6

✔

1–3

26,27

Rabies virus

<pH 6

✔

2–3

24

Lagos bat virus

<pH 6

✔

2–3

24

Marburg virus

ɸ

✔

1–3

28

Ebola virus

ɸ

✔

1–3

29

5

Virus

Fusion pH
Conditions

Restricted
by IFITMs

Active IFITM

Reference

Herpesviridae

Cytomegalovirus

Cell type
specific

Cytokine
Driven

3

20

Coronaviridae

Coronavirus

ɸ

✔

1–3

29

Human
immunodeficiency
virus

Varies

Pathway
dependent

1-3

30-33

pH >6

✔

1 best

34

Moloney leukemia
virus

X

X

No

8, 29

Lassa virus

pH >6

X

No

8

Machupo virus

pH >6

X

No

8

Lymphocytic
choriomeningitis
virus

pH >6
X

No

8

Semliki forest virus

pH >6

✔

1 and 3

34

Chikungunya

<pH 6

3

35

La Crosse virus

<pH 6

✔

1-3

36

Hantaan virus

<pH 6

✔

1-3

37

Andes virus

<pH 6

✔

1-3

37

Rift Valley fever
virus

<pH 6

2 and 3

37

Crimean–Congo
haemorrhagic fever
virus

<pH 6

X

No

37

Reovirus

<pH 6

✔

3

37

Family

Retroviridae

Jaagsiekte sheep
retrovirus

Arenaviridae

Togaviridae

Bunyaviridae

Reoviridae

6

✔

✔

Proposed mechanisms of IFITM3 anti-viral activity.
IFITM3 restriction of viral infection occurs at the stage of viral fusion and content
delivery38, focusing proposed models for IFITM3’s mechanism of antiviral activity on
alternations to the environment in which viral fusion often occurs–the late endosome. An
unbiased conjecture of possible mechanisms include (1) an indirect mechanism
whereby IFITM3 recruits a yet unknown protein/cofactor responsible for the alternation
of the fusion environment, either by changing membrane properties, or by altering the
maturation pathway of the endosomal vesicle. (2) A direct mechanism, in which IFITM3
alters the endosomal membrane’s biophysical properties such as membrane fluidity or
curvature capacity, or (3) the maturation of the endosomal vesicle, directing the viral
particle to an incompatible environment. (4) IFITM3 directly interacts with the viral
particle, interfering with the completion of fusion (Fig. 4).

Figure 4. Possible mechanisms of IFITM3 inhibition. IFITM3 inhibits viral fusion and
content delivery via a yet unknown mechanism. This interaction either acts indirectly,
recruiting an unknown protein/cofactor, or directly by disrupting the membrane fusion
environment.
7

There are currently two models for IFITM3’s antiviral restriction, each suggesting
distinctly different mechanisms: In 2013, Amini-Bavil-Olyaee et al. proposed that IFITM3
interferes with viral entry by disrupting cholesterol export from the late endosome 39.
They showed that IFITM3 co-immunoprecipitates with vesicle associated membrane
protein-A (VAP-A), that is part of the cholesterol export pathway mediated by NPC-2/1
and ORP family proteins40. As the antiviral activity of IFITM3 is impaired with the
overexpression of VAP-A, they posit that IFITM3 inhibits VAP-A, and that this interaction
is overridden by sufficiently saturating the system with VAP-A protein. As they
additionally show an increase in late endosome cholesterol in cells overexpressing
IFITM3, they propose that the interaction between IFITM3 and VAP-A interferes with
ORP-mediated cholesterol export, resulting in greater rigidity of the membrane, thus
impeding fusion and retaining the viral particle until it is degraded in the lysosome (Fig.
5).

Figure 5. Proposed mechanism for IFITM3 disruption of cholesterol homeostasis.
Fig. 7 from Amini-Bavil-Olyaee et al39. Left: under basal level conditions, cholesterol is
trafficked out of the late endosome through NPC1/2 to ORPs and ER-bound VAP-A.
Right: IFITM3 was proposed to interact with VAP-A, disrupting its interaction with ORP
and increasing cholesterol levels and membrane rigidity within the late endosome.
8

In contrast, in 2014, Desai et al.27 proposed that as an alternative to cholesterol
homeostasis, IFITM3 interferes with fusion pore formation, arresting late stage virus
entry at the point of hemifusion (in which the outer membrane leaflet of the viral
envelope mixes with the endosomal membrane, but the inner leaflet remains intact)(Fig.
6). Using a panel of membrane-binding fluorophores, and fluorescent nucleocapsid
proteins, they demonstrated that with the overexpression of IFITM3, similar or
heightened levels of envelope-lipid mixing occurs, reflecting either hemifusion, or
complete fusion. Combined with a significant IFITM3-driven decrease in viral content
delivery, these two data sets indicate that the viral particles initiate membrane fusion,
but are obstructed from completing the fusion process, retaining the hemi-fused virus
within the endosome and targeting it for degradation. Critically, they additionally show
that this mechanism is independent of cholesterol levels, and that induced accumulation
of cholesterol does not alter fusion and binding properties in A549 lung epithelial cells.
While this model presents an alternative IFITM3 function, they were unable to
confirm a precise molecular mechanism. This renews the question of direct vs. indirect
interactions, though additional publications have shown IFITM3 interfered with cell-cell
fusion in two separate models26,34. Considering the extensive differences between the
plasma and endosomal membrane both in lipid and protein composition, these
experiments reinforce the hypothesis that the mechanism is through a direct interaction
of IFITM3 with the membrane that alters the lipid properties in some manner so as to
inhibit fusion.

9

Figure 6. Proposed mechanism for IFITM3 arrest of viral hemifusion. Figure 8 from
Desai et al.27. Instead of altering cholesterol homeostasis, IFITM3 was proposed to
arrest viral hemifusion. As the paper was unsuccessful in detecting colocalization
between the viral particles and IFITM3, it is still unclear whether it is a direct interaction.
Though IFITM3’s inhibition of viral fusion and entry has been a primary research
focus, additional IFITM3 functionalities have been reported, suggesting a more complex
role in host defense: Though a host protein, IFITM proteins can be incorporated into
budding viral particles32,41, thus impairing their assembly and infectivity. IFITM3 also
plays a role in supporting adaptive immunity and regulating inflammation–memory CD8+
T cells in the lung parenchyma express higher levels of IFITM3, increasing their
resistance to secondary infections23. Respiratory DC cells from IFITM3 KO mice
showed increased susceptibility to influenza infection, leading to impaired trafficking to
lymph nodes, and CD8+ activation22. Additionally, IFITM3 was shown to be critical for
regulating IL-6 expression and lymphocyte survival in CMV infection 20, as well as down
regulating IRF3-mediated IFN-β expression during viral infection42.
10

Posttranslational modifications regulate IFITM3 traffic and activity
IFITM3 is regulated by several post-translational modifications (PTMs) that
alternately affect its antiviral activity (Fig. 7). Using metabolic labeling with the
biorthogonal chemcial reporter alkyne-palmitate (alk-16), our lab has shown that all
three cysteines (Cys) in IFITM3 are S-fatty-acylated, and that mutagenesis of these
residues to alanines (Ala) critically impairs its antiviral activity13. The trafficking of
IFITM3 is also regulated by the phosphorylation of tyrosine 20, which leads to diffuse
localization (in contrast to a punctuate morphology) and loss of antiviral activity43,44.
IFITM3 is further modified by the ubiquitination of lysines 24, 83, 88 and 10413, and the
methylation of lysine 8845, both of which have been shown to disrupt antiviral activity.
The disruption of ubiquitination by mutation of the individual lysines reduced IFITM3
protein turnover and increased its anti-viral activity. Since our laboratory discovered
IFITM3 S-fatty-acylation15, we have been especially interested in understanding how
this dynamic modification quantitatively controls IFITM3 antiviral activity.

11

Figure 7. Posttranslational modifications of IFITM3. Schematic of IFITM3 PTMs:
while Tyr20 phosphorylation, methylation at Lys 88 and ubiquitination (Ub) at Lys
24,83,88,104 interfere with IFITM3, Cys palmitoylation is essential for its antiviral
activity.

Our understanding of IFITM3 physiology and scope of antiviral activity has been
increasing over the past years. Nevertheless, these efforts have yielded mixed results in
elucidating the molecular mechanism of IFITM3 activity, prompting the exploration of
alternative experimental models. The following chapters describe our efforts towards
characterizing the endogenous state of S-fatty-acylated IFITM3, generating recombinant
protein, and its application to reconstituted liposomes for in vitro virus fusion assays.
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Chapter 2: Mass-tag labeling reveals site-specific and
endogenous levels of protein S-fatty acylation
S-fatty acylation: a dynamic post-translational modification.
The covalent coupling of fatty acids and similar carbon chain homologues to
proteins provides the cell with a spatiotemporal mechanism for controlling protein affinity
for membranes. These modifications affect stability, function, trafficking, and membrane
composition preferences46. In eukaryotic cells, long chain fatty acid modifications
primarily occur with lipids 12-18 carbons long, varying in saturation and attachment
loci47 (Fig 8A).
S-fatty acylation, which couples fatty acids to cysteines through a thioester bond,
is primarily in the form of a saturated 16-carbon chain48 and is the most common
eukaryotic post lipid modification to be dynamically modified 47. S-fatty acids are coupled
to proteins through protein acyl transferases (PATs), containing a DHHC catalytic
domain49. In humans, there are 23 different DHHC family proteins, though substrate
redundancy has complicated our understanding of targets. The cleavage of S-fatty acids
is mediated by acyl-protein thioesterase (APT)1/250, PPT151 and ABHD1752 (Fig. 8B),
though considering the broad profile of S-acylated proteins, more are likely to be
discovered. As the immune system must self-regulate inflammation to avoid an
excessive response and immunopathology53,54, the dynamic nature of S-fatty acylation
has prompted interest in understanding what role it potentially plays in innate and
adaptive immunity.
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A

B

Figure 8. Protein lipidation varies in chain length, saturation and site of
attachment. (A) Comparison of lipidation modifications varying in structure and site of
attachment. Table from Chamberlain et al.47, modified to include lysine deacylation by
SIRT255. (B) S-palmitoylation is dynamically regulated, with the addition and cleavage of
the fatty acid regulated by DHHC-PATs and thioesterases, respectively.

Our expanding knowledge of the role of S-fatty acylation in influencing numerous
cellular activities has driven the field’s continued investment in improved methods for Sfatty acylation detection, and understanding of dynamics and regulation 56. Proteome
wide profiling has made considerable strides with the development of a variety of
14

enrichment techniques that can target either endogenous proteins, or proteins labeled
by exogenous tags incorporated through the cellular machinery (metabolic labeling)57.
These tags – alkyne-modified fatty acid chemical reporters (Fig. 9A) – utilize
bioorthogonal Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC)58 to label proteins for
analysis by polyacrylamide gel electrophoresis (PAGE), or enrich for characterization by
mass spectrometry. This approach has been developed57 and used by our lab15,59 to
generate whole cell profiles that provide a first step towards discovering new
modifications.
As an alternative to metabolic labeling, thioester specific cleavage of
hydroxylamine (NH2OH) has enabled the enrichment of endogenously labeled S-fatty
acylated proteins by acyl-biotin exchange (ABE)60, and the acyl-resin capture (aclyRAC)61. These methods overcome technical limitations inherent with metabolic labeling,
and can detect S-fatty acylated proteins under physiological conditions, including exvivo tissue samples inaccessible to chemical probes62. They have yielded invaluable
profiles of endogenous lipo-proteomes, characterizing both cell types63-66 and tissues6769.

Recent advances in experimental design have also enabled Cys specific detection of

site modification, streamlining initial detection and site validation into a single data set70.

15

A

B

Figure 9. Schematic for S-fatty acylation detection and analysis. (A) For metabolic
labeling, cells are incubated with alkyne-labeled palmitate (alk-16) for several hours
prior to harvesting. Proteins are lysed, reacted with azide-functionalized reagents by
CuAAC, and analyzed by in-gel fluorescence, or processed for proteomics57. (B) With
ABE or acyl-RAC, cell lysates are capped with NEM, and the thioesters cleaved with
NH2OH. The newly generated cysteines are reacted with HPDP-Biotin71. Following
streptavidin bead enrichment, captured proteins are eluted with reducing agents and
then analyzed by Western blot or processed for proteomics59.

Albeit these advances and methodological iterations, several limitations have
persisted in quantitatively characterizing S-fatty acylation with these assays; S-acylation
levels (the number of fatty acids on a single protein) cannot be differentiated, nor could
the ratio between S-fatty acylated, and non S-fatty acylated protein (apo) be detected
within the same sample. Furthermore, metabolic labeling of a sample requires the

16

addition of exogenous source of chemical reporters, veering further away from
physiological conditions. We therefore sought to develop a new method capable of
detecting the different S-fatty acylation levels present in a protein population. This would
advance the fields ability to understand how changes in S-fatty acylation levels alter
downstream phenotypes such as localization and function.
To resolve a protein’s levels of S-fatty acylation, we have developed acyl-PEG
exchange (APE)71. This method utilizes the selective cleavage of thioesters by NH 2OH
to cleave S-fatty acids, exposing nucleophilic thiols which are then labeled with tags of
defined molecular weight. These coupled ‘mass tags’ of maleimide-functionalized
polyethylene glycol (mPEG-Mal) result in a mobility shift when analyzed by gel
electrophoresis, corresponding to the original number of S-fatty acylated cysteines. APE
enables facile detection of multiple S-fatty acylation populations of proteins, without the
drawback of affinity enrichment, or the interference of exogenous chemical reporters
(Fig. 10A).
For APE, cell samples are lysed in denaturing buffer (4% SDS), and the free
cysteines reduced with TCEP and capped with N-ethyl maleimide (NEM). After excess
NEM is removed by protein precipitation, thioesters are cleaved by incubating the
resuspended sample with NH2OH. Excess NH2OH is removed, and the exposed
cysteines are labeled with mPEG-Mal, before analysis by SDS-PAGE and western blot.
We first applied APE to the canonical S-palmitoylated protein HRas (Fig. 10B). A
peripheral membrane GTPase involved in cell division, HRas contains two Spalmitoylation sites (Cys 181, 184), as well as one thioether coupled (and therefore
NH2OH insensitive) farnesyl group at Cys 18672. To compare our overexpressed HA17

tagged HRas with endogenous level proteins, we also blotted against endogenous
calnexin, an ER chaperon protein with two known S-palmitoylation sites73.

A

B

Figure 10. APE enables the detection of S-fatty acylation levels. (A) Schematic for
APE protocol. Samples are lysed, reduced and capped with NEM. The thioesters are
then cleaved with NH2OH, labeled mPEG-mal, and analyzed by SDS-PAGE and
Western blot. (B) HA-HRas was analyzed by APE with different controls. With the
sequential addition of NEM, NH2OH, and mPEG-mal, mass shifts reflecting different
levels of S-fatty acylation are observed.
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The incubation of HEK293T cell lysates with mPEG-Mal alone (lane 2) results in
several mass shifts, corresponding with the varying availability of non-modified
cysteines. With the addition of NEM prior to mass-tag labeling (lane 3), all cysteines are
fully capped, resulting in no mass-shift. The addition of the NH2OH (lane 4) exposes
previously S-fatty acylated cysteines, which are successfully labeled with mPEG-mal.
HRas displays two mass shifts, reflecting single (*) and doubly (**) labeled populations,
corresponding with its dynamic spatial regulation through S-fatty acylation72. Additional
shifts were not observed, suggesting successful NH2OH resistance of non-thioester
based modifications. Calnexin (CANX) exhibits two mass shifts as well, in agreement
with the literature on the known S-fatty acylation sites. To show that our mass shifts are
dependent on the size of our mass-tags, samples were additionally labeled 10 kDa
mPEG-mal (lane 5). Indeed, the larger molecular weight mass tag exhibited a mass shift
twice the size of the 5 kDa tag, confirming a tag-dependent shift.
Having demonstrated a proof-of-concept - that APE can label S-fatty acylated
proteins, the protocol was optimized to ensure complete capping, cleavage and
labeling. A titration of the amount of NH2OH during a one hour incubation showed
saturating levels were obtained at 0.75 M (Fig. 11A). Saturating levels for mPEG-mal
varied depending on the molecular weight of the protein analyzed (Fig. 11B), though we
discovered that some proteins, such as Rab7 present a mPEG-mal dependent mass
shift even without NH2OH. The presence of 0.1 % Triton X-100 (copied from the ABE
protocol) did not end up affecting our results with our specific proteins (Fig. 11C) though
a critical experimental component was shown to be the inclusion of EDTA during the
cleavage of NH2OH (Fig. 11D).
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Figure 11. Optimization of APE. (A) APE does not require 0.2% Tx-100, though
removal of EDTA impairs the completion of di-PEGylation for CANX and endogenous
Ras. (B) The removal of EDTA from various stages of APE confirms it essential for
NH2OH cleavage. Titration of NH2OH (C) and mPEG-mal (D) reveals that saturating
conditions are protein specific. GFP-RAB7 exhibits an NH2OH independent mass shift,
stressing the importance of proper optimization before further assays.

To confirm the observed APE mass shifts are site specific, we compared HAHRas constructs containing single and double cysteine to alanine mutations (Fig. 12A).
These constructs were additionally analyzed by alk-16 metabolic labeling to observe
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how the results compared between the two assays (Fig. 12B). HEK293T cells were
transfected overnight with the HA-HRas constructs, and incubated with 50 μM alk-16
probe two hours prior to lysis. By APE, the absence of either or both S-palmitoylated
cysteines results in distinct mass shift patterns corresponding with the number of
available sites; single (C181A, C184A) cysteine constructs exhibited only one shift,
while double (C181,184A) cysteines did not shift at all. Alk-16 labeling exhibited similar
trends in signal, reflecting total S-fatty acylation in the sample.

Figure 12. APE and metabolic labeling of HA-HRas. 293T cells transfected with HAHRas constructs were incubated with 50 μM alk-16 and split for analysis by APE (A)
and metabolic labeling (B). APE displays mass shifts corresponding with the number of
Cys present in the HRas construct. For metabolic labeling, samples were lysed,
immunoprecipitated with anti-HA beads, and labeled with azido-rhodamine by CuAAC
prior to SDS-PAGE.
To further demonstrate the applicability of APE, we analyzed several additional
proteins that differ in topology, size and number S-fatty acylation sites (Fig. 13): CD9, a
tetraspanin with 6 reported S-fatty acylation sites74, showed 4 shifts. IFITM3, a single
pass membrane protein with three known sites, showed three shifts, and IRGM1, a
peripheral GTPase displayed a single shift. Additionally, pan-Ras antibodies were used
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to observe endogenous Ras, which exhibited double and single mass shifts. The
successful labeling of a variety of proteins provides strong evidence for the utility of
APE. This assay equips us an accessible, novel analytical approach for S-fatty
acylation, and demonstrates the potential in mass-tag labeling for investigating other
post-translational modifications.

A

B

C

Figure 13. APE can be applied to proteins with varied topologies, molecular
weights, and S-fatty acylation events. HEK293T cells were transfected with either
WT or cysteine deficient (P∆) constructs of HRas (A), IFITM3 (B), CD9 (C), IRGM1 (D)
and analyzed by APE.
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Chapter 2 methods (Published in Percher et al. PNAS 2016)
Acyl-PEG Exchange (APE)
Cell samples were lysed with 4% sodium dodecyl sulfate (SDS, Fischer) in TEA
buffer (pH 7.3, 50 mM triethanolamine (TEA), 150 mM NaCl) containing 1x protease
inhibitor cocktail (Roche), 5 mM PMSF (Sigma), 5 mM EDTA (Fischer) and 1500
units/mL benzonase (EMD). The protein concentration of the cell lysate was then
measured using a BCA assay (Thermo), and adjusted to 2 mg/mL with lysis buffer.
Typically, 200 µg of total protein in 92.5 µL of lysis buffer was treated with 5 µL of 200
mM neutralized tris(2-carboxyethyl)phosphine (TCEP, Thermo) for final concentration of
10 mM TCEP for 30 minutes with nutation. N-ethylmaleimide (NEM, Sigma), 2.5 µL from
freshly made 1 M stock in ethanol, was added for a final concentration of 25 mM and
incubated for 2 hours at room temperature. Reductive alkylation of the proteins was
then terminated by methanol-chloroform-H2O precipitation (4:1.5:3) with sequential
addition of methanol (400 µL), chloroform (150 µL) and distilled H 2O (300 µL) (all prechilled on ice). The reactions were then mixed by inversion and centrifuged (Centrifuge
5417R, Eppendorf) at 20,000 g for 5 minutes at 4 o C. To pellet the precipitated proteins,
the aqueous layer was removed, 1 mL of pre-chilled MeOH was added, the eppendorf
tube inverted several times and centrifuged at 20,000 g for 3 minutes at 4 o C. The
supernatant was then decanted, and the protein pellet washed once more with 800 µL
of pre-chilled MeOH, centrifuged again and dried using a speed-vacuum (Centrivap
Concentrator, Labconco) To ensure complete removal of NEM from the protein pellets,
the samples were resuspended with 100 µL of TEA buffer containing 4% SDS, warmed
to 37o C for 10 minutes, briefly (~5 seconds) sonicated (Ultrasonic Cleaner, VWR) and
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subjected to two additional rounds of methanol-chloroform-H2O precipitations as
described above.
For hydroxylamine (NH2OH) cleavage and mPEG-maleimide alkylation, the
protein pellet was resuspended in 30 µL TEA buffer containing 4% SDS, 4 mM EDTA
and treated with 90 µL of 1 M neutralized NH2OH (J.T. Baker) dissolved in TEA buffer
pH 7.3, containing 0.2% Triton X-100 (Fisher) to obtain a final concentration of 0.75 M
NH2OH. Protease inhibitor cocktail or PMSF should be omitted, as these reagents can
interfere with the NH2OH reactivity. Control samples not treated with NH2OH were
diluted in 90 µL TEA buffer with 0.2% Triton X-100. Samples were incubated at room
temperature for 1 hour with nutation. The samples were then subjected to methanolchloroform-H2O precipitation as described above and resuspended in 30 µL TEA buffer
containing 4% SDS, 4 mM EDTA, warmed to 37o C for 10 minutes and briefly (~5
seconds) sonicated and treated with 90 µL TEA buffer with 0.2% Triton X-100 and 1.33
mM methoxypolyethylene glycol-maleimide (mPEG-Mal, 5 or 10 kDa, Sigma) for a final
concentration of 1 mM mPEG-Mal. Samples were incubated for 2 hours at room
temperature with nutation before a final methanol-chloroform-H2O precipitation. Dried
protein pellets were resuspended in 50 µL 1 X Laemmli buffer (BioRad) and then heated
for 5 minutes at 95o C. Typically, 15 µL of the sample was loaded in 4-20% CriterionTGX Stain Free polyacrylamide gels (Bio-Rad), separated by SDS-PAGE and analyzed
by western blot. For western blots, primary antibodies used were anti-calnexin (1:2000
ab22595, Abcam), anti-Pan Ras (1:500, Ras10, Millipore), anti-mouse IFITM3 (1:1000,
ab15592, Abcam) anti-FLAG (1:1000, F1804, Sigma) anti-HA (1:1000, ab9134, Abcam),
and HRP-conjugated anti-HA (3F10, Roche). Secondary antibodies used were HRP-
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conjugated goat anti-rabbit (DC03L, Calbiochem), and goat-anti-mouse (ab97023,
Abcam). Protein detection was performed with ECL detection reagent (GE healthcare)
on a BioRad ChemiDoc MP Imaging System

Cell Culture and Transfections
HEK293T, HeLa and RAW264.7 cells were obtained from ATCC. For transfection
of HEK293T or HeLa cells, near confluent 6-well plates were transfected with 1 µg of
plasmid DNA using 3 µL of Lipofectamine 2000 reagent (Life Technologies). After 24
hours, cells were collected by scraping, centrifuged at 500 g for 2 minutes, washed with
1X PBS, snap-frozen in dry ice/ethanol bath and stored at -80o C for future use. For
NIH3T3 cells, near confluent 6-wells plates were transfected with 1 µg of plasmid DNA
with 3 µL of Lipofectamine 3000 reagent (Life Technologies). After 6 hours, the media
was replaced with fresh media to reduce toxicity of the Lipofectamine reagent. After 24
hours the cells were collected and stored for future use at -80o C. LPS (500 ng/mL,
Enzo Life Sciences) and IFN-γ (100 U/mL IFN-y, Thermo) activation of cells were
performed as previously described13.
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Acyl-Biotin Exchange (ABE)
The ABE protocol was performed as described 60. Following cell lysis, 400 µg of
total cell lysate resubjected to reductive alkylation with TCEP and NEM as described
above for the APE protocol. After the final methanol-chloroform-H2O precipitation, the
protein pellet was resuspended in 100 µL 4% SDS in 50 mM TEA, 150 mM NaCl pH
7.3, and 1 mM EDTA. The samples were split into two 50 µL aliquots and treated with
1M NH2OH or control buffer (200 µg/condition). For the NH2OH-treated sample, 150 µL
NH2OH-HPDP-biotin buffer (for 160 µL of buffer: 3.2 µL of HPDP-Biotin (50 mM stock in
DMSO, Sigma), 36.8 µL of dimethylformamide (DMF, Fisher Scientific), 3.2 µL of 10%
Triton X-100 in H2O, 112 µL of 1 M NH2OH in H2O pH 7.3, 4.8 µL H2O) was added to
the sample for a final concentration of 0.75 M NH2OH, 1% SDS (lysate:NH2OH-HPDPbiotin buffer 1:3). For the NH2OH-negative control, the samples were treated with 150
µL of HPDP-biotin buffer (for 160 µL of buffer: 3.2 µL of HPDP-Biotin (50 mM stock in
DMSO), 36.8 µL of DMF, 3.2 µL of 10% Triton x-100 in H2O, 16 µL of 500 mM TEA 1.5
M NaCl pH 7.3, 101.8 µL H2O) was added to the negative control sample for a final
concentration of 1% SDS (Lysate: Buffer 1:3). The mixture was incubated at room
temperature with end-over-end rotation for 1 hour. Proteins were precipitated
(methanol-chloroform-H2O precipitation) and resuspended in 50 µL 4% SDS 50 mM
TEA pH 7.3, 150 mM NaCl, 1mM EDTA (final concentration 4 mg/mL). 150 µL HPDPbiotin low concentration buffer (for 300 µL of buffer: 1.2 µL of HPDP-Biotin (50 mM),
13.8 µL of DMF, 6 µL of 10% Triton X-100 in H2O, 30 µL of 500 mM TEA 1.5 M NaCl pH
7.3, 249 µL H2O) was added to both samples (HPDP-biotin: lysate 3:1). The samples
were incubated at room temperature with end-over-end rotation for 1 hour, subjected to
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methanol-chloroform-H2O precipitation as described above and resuspended in 100 µL
0.2% SDS 0.2% Triton X-100 50 mM TEA, 150 mM NaCl, pH 7.3. High-affinity
streptavidin-agarose beads (Thermo, 20 µL of bead slurry/200 µg of protein) were
washed with 50 mM TEA, 150 mM NaCl, 0.2% Triton X-100, pH 7.3 (3x). The
resuspended samples were then added to the beads and incubated at room
temperature with end-over-end rotation for 90 minutes. The supernatant from the beads
was decanted and boiled with 4x Laemmli sample buffer (LSB) (supernatant:LSB:BME
3:1:0.1) at 95° C for 5 min. The beads were washed with 1% SDS in PBS for 2 minutes,
and centrifuged at 1700 g for 1 minute (2x). The beads were then washed in 4 M Urea
(Sigma) in PBS (3x), PBS (3x). The beads were boiled at 95° C for 10 minutes with 1x
Laemmli sample buffer (LSB:BME:4% SDS 50 mM TEA, 150 mM NaCl pH 7.3,
0.9:0.1:3), separated by SDS-PAGE and analyzed by western blot. Typically, 40 µg of
protein were loaded on the gel.
Acyl-Resin Assisted Capture (acyl-RAC).
Following reductive alkylation of total lysate (400 µg) with TCEP and NEM as
described above for the APE and ABE, the samples were resuspended in 50 µL 4%
SDS, 50 mM TEA, 150 mM, 150 mM NaCl, 1 mM EDTA, pH 7.3. The samples were
split into two 25 µL aliquots - or + NH2OH (200 µg/condition). For the NH2OH-treated
sample, 75 µL NH2OH 1 M, 0.2% Triton X-100, pH 7.3 in H2O was added to the
“+NH2OH” sample for a final concentration of 0.75 M NH2OH, 1% SDS (Lysate: NH2OH
solution 1:3). For the negative control not treated with NH2OH, 75 µL 50 mM TEA, 0.2%
Triton X-100, 150 mM NaCl pH 7.3 was added to the samples (“-NH2OH”) for a final
concentration of 1% SDS (Lysate:Buffer 1:3). To capture proteins with free thiols, thiol27

sepharose beads 6B (T8387,Sigma) were soaked in 1 mL H 2O for 30 minutes. Beads
were washed three times with 0.5 mL of 50 mM TEA 150 mM NaCl, 0.2% Triton X-100,
pH 7.3. Each sample (100 µL of -/+ NH2OH) was added to the thiol-sepharose beads
(200 µg of proteins/6.25 mg thiol-sepharose beads) and incubated at room temperature
for 3 hours with end-over-end rotation. The supernatants from the beads were decanted
and boiled with 4x Laemmli sample buffer (LSB:BME:supernatant 0.9:0.1:3) for 5 min.
The beads were washed with 1% SDS in PBS (3 x 2 min), 4 M Urea in PBS (3x), PBS
(3x). Beads were boiled at 95o C for 10 minutes with 1x Laemmli sample buffer
(LSB:BME:4% SDS 50 mM TEA, 150 mM NaCl pH 7.3, 0.9:0.1:3), separated by SDSPAGE and analyzed by western blot. Typically, 40 µg of protein were loaded on the gel.
Metabolic labeling and in-gel fluorescence profiling
For metabolic labeling of cells with alkyne-palmitic acid reporter (t), HEK293T
cells transfected with HA-HRas constructs or NIH3T3 cells transfected with HAmIFITM3 constructs were incubated for two hours with 50 µM alk-16 (synthesized as
previously reported ) in DMEM containing 2% (v/v) charcoal-dextran stripped FBS (Lot:
AZA180873, HyClone). Cells were harvested by trypsinization, washed once in PBS,
pelleted and lysed in 1% (w/v) Brij 97 (Sigma) in 50 mM TEA 150 mM NaCl pH 7.3 with
5X concentration of EDTA-free protease inhibitor cocktail (Roche). Total protein
concentration was measured by BCA assay (Life Tech). For immunoprecipitation, 200
μg of total protein was added to 20 μL of anti-HA antibody–conjugated agarose (Sigma)
in a total volume of 250 μL and rocked at 4° C for 16 hours. Agarose beads were
washed twice by resuspension in 1 mL of wash buffer (1% Triton X-100, 1% sodium
deoxycholate (Sigma), 0.1% SDS in 50 mM TEA, 150 mM NaCl pH 7.3) and centrifuged
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at 3500 g for 30 seconds. The beads were then resuspended in 20 μL of 1% (w/v) Brij in
in 50 mM TEA 150 mM NaCl pH 7.3 and 5 μL of CuAAC reactant solution (0.5 μL of 5
mM azido-rhodamine (final concentration 200 μM), 1 μL of 50 mM freshly
prepared CuSO4·5H2O in H2O (final concentration 2 mM, Sigma), 1 μL of 50 mM freshly
prepared TCEP (final concentration 2 mM) and 2.5 μL of 2 mM tris[(1-benzyl-1H-1,2,3triazol-4-yl)methyl]amine (TBTA) (final concentration 200 μM, synthesized as previously
reported). Beads were rocked with the CuAAC reactant solution at room temperature for
1 hour and washed twice with wash buffer as described above. The proteins were
eluted addition of 30 μL 1X Laemmli sample buffer (LSB:BME: 4% SDS 50 mM TEA,
150 mM NaCl pH 7.3, 1:0.1:3), heated for 5 minutes at 95° C and separated by SDSPAGE. In-gel fluorescence scanning was performed using a Typhoon 9400 imager
(Amersham Biosciences). Western blots for HA-tagged proteins were performed using
an anti–HA tag-HRP conjugated antibody (1/1,000 Roche).
Influenza virus infection
NIH3T3 cells were transfected with Lipofectamine 2000 (Thermo) overnight in
12-well plates using 1 μg of plasmid per well. Media was removed and replaced with
400 μL of media +/- influenza virus strain A/Puerto Rico/8/34 (H1N1, commonly referred
to as PR8) at an multiplicity of infection (MOI) of 5 for each well. Infection was allowed
to proceed for 18 hours. Cells were collected and fixed for 10 minutes with 4%
paraformaldehyde. Fixed cells were then permeabilized with 0.1% Triton X-100 in PBS
for 10 minutes and blocked with 2% FBS in PBS for 20 minutes. All antibody staining
and washing was performed using the 0.1% Triton X-100 solution. Staining with antiHA antibody (HA.11, Covance, 1:1000) was performed for 20 min at room temperature
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followed by three washes and staining with anti-mouse secondary antibody conjugated
to Alexafluor-488 (Life Technologies, 1:1000). After an additional three washes, cells
were stained with anti-influenza NP antibody (ab20343, Abcam, 1:300) that was directly
conjugated in-house to Alexafluor-647 using the 100 ug antibody labeling kit from Life
Technologies. Samples were analyzed using a Becton Dickinson FACSCanto II flow
cytometer and HA-positive cells were analyzed for the percentage of cells staining
positive for influenza NP indicating cellular infection using Flowjo software as previously
described.
Immunofluorescence analysis
For the analysis of mIFITM3 colocalization with endosomal/ lysosomal markers, 50,000
NIH3T3 cells/well were plated in a 24 well plate, and co-transfected the next day with
0.25 μg HA-IFITM3 and 0.25 μg of either GFP-Rab5, GFP-Rab7 (54244, addgene), or
LAMP1-GFP (34831, addgene) with 1.5 μL Lipofectamine 3000 (Thermo) for four hours,
then incubated with fresh media for an additional 12 hours. Cells were fixed for 15 min
with 3.7% paraformaldehyde, washed 3x with PBS, permeabilized with 0.1% saponin in
PBS for 10 minutes, and blocked for 60 minutes with 1% BSA in PBS. All antibody
staining and washing was performed with 0.1% saponin in PBS. Cells were incubated
with goat anti-HA antibody (1/1000, ab9134, Abcam) in 1% BSA for one hour at room
temperature. After three, 5 minute washes, samples were incubated with donkey antigoat antibody conjugated to Alexafluor-647 (1/1000, A-21447, Invitrogen) in 1% BSA.
Cells were washed, and mounted using ProLong Gold antifade reagent (Invitrogen).
Images were obtained from an Inverted Zeiss Axio Observer Z1 microscope, and
processed with ImageJ. Pearson coefficient was calculated using Imaris 8 software.
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Chapter 3: Characterization of endogenous IFITM3 S-fatty
acylation.
Having confirmed with model proteins that APE can observe different levels of Sfatty-acylation by western blot, we further explored the S-fatty acylation of IFITM3.
Previous work in our lab has shown by alk-16 metabolic labeling that IFITM3’s three
cysteines are S-fatty acylated, and that the mutation of all three to Ala disrupt anti-viral
activity15. Additionally, the mutation of C72 alone was sufficient to disrupt anti-viral
activity against IAV and Dengue virus10. While this suggests S-fatty acylation plays a
role in IFITM3’s function, it was still unclear how many sites were modified
simultaneously. Understanding S-palmitoylation levels would further our understanding
of the physiological state of IFITM3, and how it relates to its anti-viral activity.

S-fatty acylation levels of murine IFITM3
We first analyzed murine IFITM3 (mIFITM3), as doing so furthers our
understanding of S-fatty acylation levels in a commonly used model for in vitro13 and in
vivo21,75 experimental assays. Incubation times for mPEG-mal and NH2OH were
compared for background mass shifts and completion of cleavage respectively (Fig. 14).
Both conditions showed complete labeling and cleavage under standard conditions
used for other samples. To determine how specific Cys sites contribute to mIFITM3 Sfatty acylation levels, overexpressed HA-tagged constructs were analyzed by APE and
alk-16 metabolic labeling. Similar to earlier reports in DC2.4 dendritic cells 13, alk-16
incorporation onto mIFITM3 decreased in a cysteine dependent manner(Fig. 15A);
C71A and C105A showed a similar loss of labeling, while C72A showed the greatest
decrease.
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Figure 14. mPEG-Mal concentration optimization of IFITM3. NIH3T3 lysate was
analyzed by APE with varying concentrations of mPEG-Mal. No change in ratios was
observed at concentrations higher than 1 mM. The number of PEGylation events are
indicated by asterisks (*).
With APE, overexpressed WT IFITM3 displayed four distinct bands, reflecting the
presence of non-modified (apo), mono, di, and tri-PEGylated populations (Fig. 15B, 2nd
lane). In comparison, the individual and dually-mutated cysteines show distinct
PEGylation patterns: the mutation of either Cys 71 or Cys 105 to alanine, shows two
mass shifts (mono, and di-PEGylated) while the mutation of C72A shows only one (4th
lane). To elucidate how Cys specific S-fatty acylation correlates with anti-viral activity,
we next compared the differences in viral infectivity in cells transiently overexpressing
the IFITM3 constructs (Fig 15C). C71A displayed similar infection levels to that of the
WT, while the mutation of C72 or C105 interfered with viral inhibition. This data,
combined with the metabolic labeling, indicate that S-fatty acylation levels of mIFITM3
alter the anti viral activity. While it is impossible to discern whether a specific S-acylated
population is more active, the dually mutated constructs show that the presence of a
single S-fatty acylation site at Cys 72 (C71,105A) is sufficient to restore a significant

32

portion of the anti-viral activity. Cys 72’s contribution to protein function, together with
the disruption of dual, and tri-PEGylated levels by APE suggests that its S-fatty
acylation may play a key role in the anti-viral activity of the protein.

A

B

C

Figure 15. Murine IFITM3 APE PEGylation levels and antiviral activity. (A) NIH3T3
cells transfected with HA-mIFITM3 constructs were labeled for 2 hours with 50 μM alk16. Cell lysates were prepared with Brij-97, the HA constructs immunoprecipitated with
anti-HA agarose-beads, reacted with azide-rhodamine by CuAAC, separated by
SDS/PAGE, and visualized by fluorescence gel scanning. (B) NIH3T3 cells were
transfected with similar HA-mIFITM3 constructs and analyzed by APE. The number of
PEGylation events are demarcated by asterisks (*). (C) NIH3T3 cells were transfected
with HA-mIFITM3 constructs, followed by infection with PR8 influenza virus at a
multiplicity of infection of 5, for 18 hours. Cells were fixed, permeabilized, stained with
anti-influenza NP antibody and analyzed by flow cytometry. Graph shows anti-influenza
NP+ cells for each condition. Average of triplicate. Error bar represents SEM
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Though the overexpressed constructs of IFITM3 are critical for understanding the
role of Cys specific S-fatty acylation, our method of transient transfection results in nonhomogenous transfection, at higher expression levels than endogenous IFITM3 (data
not shown). Both can potentially distort the levels of S-fatty acylation. We therefore
determined the endogenous levels of S-fatty acylation levels of mIFITM3 in mouse RAW
264.7 Macrophage, and NIH-3T3 fibroblast cell lines (Fig. 16). Both cell types exhibited
three mass shifts, with minimal apo-protein, indicating that the majority of endogenous
IFITM3 is S-fatty acylated at least once. This data indicates 7 possible combinations of
S-fatty acylation are physiologically present in cells.

C71A: Complete
antiviral activity.

ML C72: minimal
modification for
improved antiviral
activity.

Figure 16. APE of endogenous murine IFITM3. Left: Possible S-fatty acylation
isoforms observed by APE. Mouse macrophage (Raw 264.7) and fibroblast (NIH3T3)
cell lines were incubated overnight with IFN-γ and LPS, and analyzed by APE. The
number of PEGylation events is indicated by asterisks (*). Right: APE mass shifts
cannot discern between different combinations of S- acylation. Possible S-fatty acylation
isoforms are described that would reflect a corresponding mass shift.
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APE analysis of S-fatty acylation levels of human IFITM3.
Similar to mIFITM3, overexpressed human IFTIM3 (hIFITM3) in HEK293T cells
show by APE three PEGylation levels for WT hIFITM3 (Fig. 17A). Both C71A, and C72A
show primarily one PEGylation shift, of similar signal intensity, different slightly from the
mIFITM3 constructs, where C71A contains two shifts. C105A shows two shifts, as
observed in mIFITM3. For the double Cys mutants, the presence of Cys72 was
sufficient to retain similar mono-PEGylated levels to the single Cys mutants.
Interestingly, when containing only Cys 71, or Cys105 (C72,105A, C71,72A,
respectively), a large decrease in signal was observed, suggesting an overall loss of Sfatty acylation.
We next compared the antiviral activity of the hIFITM3 Cys constructs (Fig. 17B).
As with mIFITM3, C71A did not alter its activity, with similar levels of infected cells to
that of WT. C72Ala had higher levels of infection, though less than the vector or triple
mutant construct (C71,72,105A). With the double mutants, Cys71 alone (C72, 105A)
resulted in a complete loss of function, while Cys72 alone (C71, 105A) retained partial
levels of activity. Notably, distinct from mIFITM3, Cys105 alone (C71,72A) showed
similar levels of antiviral activity to C71,105A. This indicates that a minimal S-acylation
construct of Cys105 is sufficient to retain a similar level of anti-viral activity to that of
Cys72. For endogenous hIFITM3 S-acylation, A549 cells were analyzed by APE after
overnight activation with IFN-у (Fig. 17C). A549, a human lung type II alveolar epithelial
cell line
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is a clinically relevant tissue type for investigating IFITM3 expression.

Interestingly, a notable difference in APE PEGylation levels are observed in comparison
to endogenous mIFITM3; the majority of the protein is dually-PEGylated, and no tri35

PEGylated level is observed. This indicates that most of the protein is dually S-fatty
acylated, and that six possible combinations are potentially present (Fig. 17D). As the
disruption of Cys71 does not alter anti-viral activity, the likely S-acylated state of IFITM3
in A549 is the dually-S-acylated C72,105.
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Figure 17. APE and antiviral activity of human IFITM3. (A) HA-hIFITM3 constructs
were expressed in HEK293T cells and analyzed by APE. PEGylation events are
indicated by asterisks (*). (B) HEK293T cells transfected with wild-type, and cysteine
mutant constructs of HA-hIFITM3, were infected with PR8 influenza virus at an MOI of 5
for 18 h. Cells were fixed, permeabilized with 0.1% Triton X-100, and stained with antiinfluenza NP antibodies. Graph of influenza-NP+ cells for each condition. Error bars
represent SEM, N = 3. (C) IFN stimulated A549 cells were analyzed by APE.
PEGylation events are indicated by asterisks (*). (D) Depiction of possible S-fatty
acylation combinations in C.

37

Chapter 4: Generation of recombinant IFITM3 and lipidated isoforms.
Since the discovery of IFITM3 anti-viral activity38, a considerable body of work
has been published on its localization, post-translational modifications13 and range of
antiviral activity (table 1). While it has previously been shown that the point of
interference is viral content delivery27,38, the mechanism of IFITM3 activity remains
controversial. Conflicting reports make it unclear whether IFITM3 directly interacts with
the virus, alters the late endosome membrane environment, or indirectly interacts with
an unknown cofactor (Fig. 4). To eliminate the complexity of the cellular environment
and selectively control potential key parameters of IFITM3’s mechanism (membrane
lipid composition, protein concentration etc.) we directed our efforts towards the
generation of recombinant human IFITM3 (rIFITM3). This enables a minimalist model of
reconstituted protein in liposomes (proteoliposomes) and supported bilayers for viral
fusion assays, allowing us to address whether IFITM3 alone is capable of inhibiting viral
fusion.
Generation of recombinant IFITM3.
To minimize interfering factors, we designed the purification of rIFITM3 in a
manner that limited denaturation of the protein, or retained any tags used for enrichment
and purification17. We therefore utilized the His-SUMO tag that both increases the
solubility of membrane proteins, and is cleaved C-terminal to the SUMO dual-glycine
motif, generating native IFITM377 (Fig. 18B). Building off the purification conditions for
the similarly sized SNARE membrane proteins78, we were able to enrich rIFITM3 at
concentrations as high as 1 mg / mL, and isolate purified rIFITM3 through the use of
size exclusion chromatography (SEC, Fig. 18C).
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Figure 18. Purification of recombinant IFITM3. (A) Schematic of rIFITM3 construct
containing HIS tag, cleavable SUMO domain, and codon-optimized hIFITM3. (B)
Immobilized metal affinity chromatography (IMAC) is used to enrich and purify rIFITM3.
WCL: Whole cell lysate. FT: Flow through. W: Wash. (C) SEC improves purity of
rIFITM3 and isolates the sumo domain from the rest of the sample.
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Lipidation of recombinant IFITM3.
A critical aspect of generating rIFITM3 is replicating the correct post-translational
modifications. To emulate S-fatty acylation, rIFITM3 constructs containing one or two
Cys were modified with a maleimide-palmitate (mal-palm) to introduce a covalent
saturated 16 carbon chain analog (Fig. 19). We have previously used maleimide
(chapter 2) to specifically modify cysteines under similar conditions.
To confirm that we can successfully label rIFITM3 with our mal-palm analog, we
first tested and optimized the labeling of Cys72 on rIFITM3. Labeling with mal-palm
resulted in a slower migration during analysis by SDS-PAGE. While the protein did not
undergo complete labeling at 4 °C (Fig. 19B) , and precipitated at RT, we observed near
complete labeling at 15 °C , in a Cys-specific manner, indicating the gel-shift was not
due to background labeling. Labeling was further confirmed by MALDI-TOF mass
spectrometry (Fig. 19C).
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4 °C Overnight

15 °C

C71,105A

C71,72,105A

D

M/Z

IFITM3 C71,72,105A
14535.92 Dalton
+1H
+2H
+3H

M/Z

IFITM3 C71,105A + Mal-Palm
14887.97 + 321.5 Dalton
+1H
+2H
+3H

Expected

14536.93

7268.97

4846.3

Expected

14888.9

7444.9

4963.7

Observed

14534

7268.4

4845.2

Observed

14900

7445.2

4962.7

Figure 19. Mimicking S-fatty acylation of rIFITM3 with maleimide-palmitate. (A)
Schematic of rIFITM3 labeling. Thiol-specific maleimide covalently labels rIFITM3,
introducing a saturated 16 carbon chain. (B) Labeling optimization of Cys 72 rIFITM3.
(C) Cysteine specificity of mal-palm. Cys 72 rIFITM3 (C71,105A) shows a Cys
dependent mass shift when analyzed by SDS-PAGE. apoIFITM3 (containing no
cysteines) under similar conditions does not shift. (D) MALDI-TOF confirmation of malpalm labeling.
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Having confirmed that we can specifically label rIFITM3 Cys72, we generated a
panel of mal-palm labeled rIFITM3 isoforms to determine whether site-specific lipidation
alters the efficiency of anti-viral activity. Analysis of A549 cells by APE showed the
majority of endogenous IFITM3 displayed two mass-shifts, indicating that most of
IFITM3 is likely dually S-fatty acylated (Fig. 20). This reduced the complexity of our
panel of rIFITM3 isoforms, as it implies that the triple-S-fatty acylated state does not
occur in our tested human cell lines. As C71A does not compromise the anti-viral
activity of hIFITM3 and a significant portion of activity was restored in the presence of a
mono-lipidated Cys72, or Cys105 (Fig. 17B), we first generated three different mal-palm
constructs: mono-lipidated C72 (ML-C72), mono-lipidated C105 (ML-C105), and duallylipidated C72,105 (DL-C72,105) (Fig 20).

Figure 20. Mal-palm labeling of rIFITM3 S-fatty acylation isoforms. APE of A549
cells reveal that the majority of endogenous IFITM3 is dually lipidated (**). To generate
the relevant isoforms, mono-lipidated Cys 72, and 105 (*), and dual lipidated Cys
72,105 were reacted with mal-palm.
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To optimize labeling of rIFITM3 with mal-palm for the additional rIFITM3
constructs, incubation times and concentrations were varied, and compared by SDSPAGE (Fig. 21A,B). The constructs were then labeled and purified under optimal
labeling conditions and confirmed by MALDI-TOF mass spectrometry (Fig. 21C,D).
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)

B

C

D

IFITM3 C71,72A + Mal-Palm
14567.98 + 321.5 Dalton
M/Z
+1H
+2H
+3H
Expected 14889.99 7445.498 4964.003
Observed
14893
7447.5
4962.8

IFITM3 C71A + 2x Mal-Palm
14600.04 + 2x 321.5 Dalton
M/Z
+1H
+2H
+3H
Expected 15244.047 7622.527 5082.02
Observed
15242
7622.3
5083.4

Figure 21. Mal-palm labeling optimization and mass-spec confirmation. (A)
rIFITM3-Cys 105 was incubated with 1.0 mM TCEP and up to 2.5 mM Mal-Palm
(controls were incubated with 5% DMSO). A single mass shift (*) was observed. Chosen
conditions for future purifications are highlighted in red. (B) rIFITM3-Cys 72,105 was
incubated with 1.0 mM TCEP and up to 1.0 mM mal-palm. Two discernible mass shifts
were observed (*, **), though the majority of the protein signal was observed with the
double shift. Chosen conditions for future purification are labeled in red. MALDI-TOF
mass spectrometry confirmed single labeling of IFITM3 C71,105A (C), and double
labeling of IFITIM3 C71A (D).
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Chapter 4 Methods:
Generation of Recombinant IFITM3:
To improve purification human IFITM3, the sequence was optimized for bacterial
expression:
ATGAACCACACGGTCCAGACGTTTTTCTCGCCGGTCAACTCGGGCCAGCCGCCGAACTAC
GAAATGCTGAAGGAAGAACACGAAGTGGCCGTGCTGGGTGCACCGCATAACCCGGCACC
GCCGACCTCAACGGTTATTCATATCCGTAGCGAAACCTCTGTCCCGGATCACGTGGTTTGG
TCGCTGTTTAACACGCTGTTCATGAATCCGTGCTGTCTGGGCTTTATTGCGTTCGCCTATA
GTGTTAAATCCCGTGATCGCAAGATGGTCGGCGACGTGACCGGTGCACAGGCTTACGCGT
CTACGGCTAAATGCCTGAATATTTGGGCACTGATCCTGGGTATTCTGATGACGATTCTGCT
GATTGTGATTCCGGTCCTGATTTTTCAAGCGTATGGCTAA

Plasmid Construct Design:
Sequence optimized IFITM3 was cloned by Gibson assembly into a PET 28c plasmid
immediately 3’ to a HIS-Sumo sequence, designed by Christopher D. Lima79. For Cys
mutant constructs, QuikChange Lightning, and QuikChange Multi Site-Directed
Mutagenesis kits (Agilent) were used to mutate the needed number of cysteines to
alanines.

Induction and Enrichment of IFITM3
The Sumo-IFITM3 construct was transformed into the BL-21 LOBSTR cell line80
containing the RIL plasmid (BL21-CodonPlus-RIL strain, Agilent) for increased copies of
tRNA argU (AGA, AGG), ileY (AUA), leuW (CUA). Single colonies were grown overnight
in LB media containing kanomycin (50 μg / mL) and chloramphenicol (25 μg / mL). The
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following day, overnight cultures were diluted 1:30 in 1 L LB with kanomycin, and
incubated at 37 °C to an O.D. of 0.6 the culture was then transferred to 18 °C, induced
with 0.5 μM IPTG, and incubated overnight for 16 – 20 h. The following day, aliquots of
500 mL of cultures were spun down at 4,000 g for 15 min, and the bacterial pellet snap
frozen in liquid nitrogen for future use. On the day of purification, a 500 mL bacterial
pellet was thawed on ice, and resuspended in 40 mL Buffer A (25 mM HEPES, 100
mM KCl, pH 7) with 2% w/v Triton-X 100, and 1x protease inhibitor mixture (Roche). If
the purified protein contained any cysteines, 1 mM β-mercaptoethanol (Sigma) was
added. The resuspended pellet was incubated at room temperature (RT) with 10 mg
lysozyme, then sonicated (Sonic Dismembrator Model 500, Fisher Scientific) for one
minute (30% power, 1 second on, 1 second off). The sample was inverted several times
to ensure mixture of lysate. Sonication was repeated twice more to ensure complete
lysis. After sonication, the sample was diluted 2.5 fold in Buffer A without Triton-X 100
(final volume 100 mL, 0.8% Triton-X 100), and spun down at 40,000 g for 45 min
(Beckman Coulter Optima XL-100K Ultracentrifuge).
During centrifugation, 12 mL of resuspended cobalt beads (‘Talon metal affinity
resin’ Clontech) were washed 1x with water, and 2x with Buffer A. Post spin, the
supernatant was collected and the cobalt beads added for two hours with nutation at 4
°C. The beads were then collected in an XK16/20 Column (Akta), and eluted using an
AKTAFPLC chromatography system. It is during this stage that the detergent is
switched from Triton-X-100 to 1% octyl glucoside (Anatrace). Using a two pump
protocol, the beads were treated stepwise with varying ratios of two different buffers:
Buffer B (25 mM HEPES, 100 mM KCl, 1% octyl glucoside, pH 7), and Buffer B-imid,
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identical to Buffer B but containing 400 mM imidazole. If a construct with a cysteine was
present, both buffers contained 1 mM neutralized TCEP (Thermo). BME contains a
thiol, which interferes with the future step of coupling the palmitate. The beads were
washed with 20 mL buffer B, then 20 mL of 90% Buffer B, 10% Buffer B-imid. Finally,
the protein was eluted with 20 mL Buffer B-imid, and collected in two mL fractions. After
the elution, fractions corresponding with the peak of the protein were incubated
overnight with nutation and ULP1 (1 mM TCEP was added if apoIFITM3 was being
purified), and analyzed the following day by SDS-PAGE. After cleavage of the SUMO
domain was confirmed, the appropriate fractions were collected and mixed, and 2 mL
fractions snap frozen in a dry-ice ethanol bath. Note: Reducing agents such as TCEP or
DTT are necessary for ULP1 activity. If the sample did not require alkylation with
maleimide-palmitate (i.e. apoIFITM3), then the SUMO domain was separated from the
native IFITM3 by size exclusion chromatography (SEC) in Buffer B (10/300 GL, AKTA).
In our hands, the SUMO domain consistently elutes after the IFITM3, making size
exclusion a useful method to both remove background proteins as well as the
enrichment tag.
Maleimide-Palmitate Synthesis
Synthesis by Rafal Wiewiora. Protocol from J. Med. Chem., 2009, 52, 7410-7420.
A round bottom flask was charged with 0.68 g of triphenylphosphine (2.57mmol, 0.9 eq.)
and 17.5 ml of tetrahydrofuran. The flask was placed under argon and cooled to -78
°C.1.18 ml of the 40% solution of diethyl azodicarboxylate in toluene (2.57 mmol, 0.9
eq.) were added over a period of 3 minutes. The resulting mixture was stirred for 5
minutes, after which a solution of 0.7 g of hexadecan-1-ol (2.87 mmol, 1 eq.) in a
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minimal amount of THF (prepared in an argon purged vial) was added over a period of 1
minute. The resulting solution was stirred for 5 minutes. The flask’s septum was then
removed under the protection of an argon curtain and 0.125 g of neopentyl alcohol (1.43
mmol, 0.5 eq.) and 0.25 g of maleimide (2.57 mmol, 0.9 eq.) were added as solids. The
flask was closed again under argon and the reaction mixture was stirred for 5 minutes,
after which the cooling bath was removed and the reaction stirred at room temperature
for 16 hours, then at 40 °C for 2 hours. After full conversion was indicated by TLC, the
solvent was evaporated in vacuo. The resulting solid was purified by silica flash
chromatography (loading and elution in dichloromethane). N-1-hexadecylmaleimide was
obtained after high vaccum drying (0.481 g, 52%). 1H NMR (400 MHz, CDCl3) δ ppm
0.88 (t, J=6.59 Hz, 3 H) 1.25 (br. s., 26 H) 1.53 - 1.60 (m, 2 H) 3.51 (t, J=7.23 Hz, 2 H)
6.68 (s, 2 H). 13C NMR (100 MHz, CDCl3): δ ppm 14.09, 22.67, 26.73, 28.52, 29.11,
29.34, 29.46, 29.53, 29.64, 31.90, 37.93, 134.00, 170.87. Reference: J. Med. Chem.,
2009, 52, 7410-7420.
Maleimide-Palmitate Labeling of IFITM3
Labeling was completed after cleavage of the His-SUMO-IFITM3 construct with ULP1
protease. By doing so before the size exclusion, excess mal-palm is removed in
addition to the SUMO domain and background proteins. Cleaved rIFITM3 is incubated
with 1 mM TCEP (neutralized) and 0.5 mM Maleimide-Palmitate (stock solution- 10 mM
in DMSO) for 2 hours at 15 °C with shaking. Temperature control is either by incubation
in a bacterial incubation shaker while shaking at 100 rpm, or in a cold room on an
Eppendorf Thermomixer heated to 15 °C. After labeling, the sample is spun down for 10
min at 20,000 x g and separated by size exclusion chromatography.
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Confirmation of rIFITM3 maleimide palmitate labeling through MALDI-TOF.
MALDI –TOF mass spectrometry was of rIFITM3 constructs with generous help of the
laboratory of Dr. Brian Chait at Rockefeller University. IFITM3 was prepared for MALDITOF analysis using the ultra thin layer method81. Briefly, first a MALDI sample plate was
prepared with a thin layer of saturated 4-HCCA (Sigma) prior to use (4-HCCA plates will
last over a year when stored properly). In preparation for sample analysis, (1)
Eppendorf tubes were washed by vortexing with acetonitrile for several seconds and
thoroughly dried. (2) A saturated solution of 4-HCCA was prepared by resuspending a
dried sample of recrystalized 4-HCCA in a solution of formic acid, water, isopropanol
(FWI) at ratios of 3:1:2 : the dried sample was resuspended in 100 μL isopropanol, and
rigorously vortexed for 2 minutes. 150 μL formic acid was then added, and the solution
vortexed rigorously again. Finally, 50 μL water was added, and vortexed a final time.
The solution was then centrifuged for 6 min at 14,000 rpm, and the soluble fraction
carefully decanted with a pipette.
Samples of rIFITM3 were diluted 1/10 in 4-HCCA solution in an acetonitrile
cleaned tube. The sample was then spotted onto the MALDI sample plate, and
vacuumed off once a precipitate was seen to form. The spotted sample was then
washed 2x with chilled 0.1% TFA in water, and loaded within half an hour into the mass
spectrometer (Spiral TOF JMS-S3000, JEOL). Samples were analyzed at a late pulse
rate of 500 Hz, at 31-33 % intensity, with a 750 ns lag time between laser pulse and
sample capture.
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Chapter 5: Production and anti-viral activity of IFITM3
proteoliposomes.
To explore the function of IFITM3 during viral fusion, it is necessary to use an
appropriate lipid environment. Membrane proteins are purified using a variety of
amphipathic detergents that enable solubilization by micelles containing hydrophobic
interiors82. In contrast, viral fusion occurs at phospholipid bilayers, which vary
considerably from detergents in structure, heterogeneity83, and stabilizing properties84.
To incorporate rIFITM3 into the phospholipid bilayer, it is necessary to (1) generate the
lipid bilayer, (2) incorporate the protein, and (3) remove the detergent that could alter
the membrane properties in future experiments.
1) Lipid-bilayer formation through liposomes.
A well-established model for investigating membrane proteins in lipid bilayers is
the liposome. A soluble, single-lamellar spherical bilayer, liposomes can be generated
from a wide range of lipid compositions and sizes (Table 2). Protein containing
liposomes (proteoliposomes) have been used extensively to characterize membrane
proteins85 and protein mediated membrane fusion86, and provide an excellent model for
viral-fusion inhibition through bulk fusion assays.
Table 2. Sizes and formation techniques for unilamellar liposomes.
PC: Phosphatidylcholine. PS: Phosphatidylserine. PE: phosphatidylethanolamine.
Class of Liposome

Diameter
(nm)

Formation Technique

Example Lipid
Compositions

Small Unilamellar Vesicle (SUV)

20 - 100

Sonication

PC/PS/PE87

Large Unilamellar Vesicle (LUV)

100 –
1000

PC/PS88, PC/PE89,
PC/Chol90

Giant Unilamellar Vesicle (GUV)

1000 +

Extrusion, Rapid
Dilution85
Electro swelling,
Spontaneous swelling88
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PC, PC/Chol91

For liposome generation in the range of 100 – 1000 nm (large unilamellar vesicle
- LUV), there are two commonly used techniques – extrusion, and rapid dilution85. For
extrusion, multi-lamellar liposomes are formed by freeze thawing a detergent free lipid
solution, and then passed through a filter membrane of defined size until unilamellar
vesicles are formed. While membranes with pore sizes up to 400 nm diameter can be
used92, LUV preformation complicates protein incorporation into the lumen. We
therefore used rapid dilution, which relies on the resuspension of lipids in detergent
containing buffer (1% w/v octyl glucoside (OG)) then diluting below the critical micelle
concentration85 (CMC). The CMC is the concentration below which the detergent is no
longer stable in a micellar structure, leading to its disassembly and inability to solubilize
hydrophilic domains of lipids or proteins (Fig. 22A). The result of this rapid dilution is the
spontaneous formation of unilamellar lipid vesicles.
Proper formation of LUV can be rapidly affirmed through dynamic light scattering
(DLS), which determines the particle diameter via fluctuations in light scattering and the
subsequent autocorrelation curve93 (Fig. 22B). Under our formation conditions and lipid
composition, we consistently observe an average diameter of 80 nm (Fig. 22C). To
measure the efficiency of liposome formation, a total-phosphate assay94 is used to
determine phospholipid concentrations after dialysis. We observe similar values for all
conditions, in the range of 0.5 mM, indicating a lipid retention of ~60% (data not shown).
2) Incorporation of IFITM3 into the proteoliposomes
In contrast to the extrusion method, a key advantage to liposome formation
through rapid dilution is the ability to introduce proteins during the formation of the
liposome itself86. Rapid dilution disrupts the detergent micelle suspension of the both
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the lipid and recombinant protein, leading liposome formation and protein incorporation
into the lipid bilayer, with an equal likelihood of incorporation into the lumen of the LUV.
This is critical for investigating potential IFITM3-virus interactions, the physiological
topology of which is IFITM3 is on one side the membrane, and the viral particle on the
other17,26.

A

B

C

~ 40 nm radius

Figure 22. Rapid dilution of detergent solubilized lipid-protein leads to formation
of unilamellar proteoliposomes. (A) The rapid dilution below the CMC of octyl
glucoside drives disassembly of the detergent micelle, leading to formation of
unilamellar LUVs. (B) DLS autocorrelation curves of empty LUVs, proteoliposomes with
rIFITM3 or VAMP2 show similar trends. (C) Derivatization of LUV diameter from
autocorrelation curves shows a consistent LUV radius of 40 nm.
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3) Dialysis of detergent
With the rapid dilution method, the detergent is diluted to a concentration below
the CMC (for OG it is approximately 0.6% w/v86) and is no longer in micellar form. While
the detergent no longer solubilizes rIFITM3 (forcing it into the lipid bilayer), it is possible
that detergent molecules will intercalate into the membrane, potentially altering the
biophysical properties of the lipid environment. The final proteoliposomes solution is
therefore dialyzed overnight in Buffer A without any detergent. After dialysis, the
liposomes were analyzed for size, and total phospholipid content.
To confirm the incorporation of the protein into the proteoliposomes, samples
were centrifuged in a Histodenz density gradient (an alternative to sucrose)95, and
fractions collected and analyzed by SDS-PAGE. For all protein constructs we observe
that the majority of the protein distributes to the top fraction of the gradient, reflecting its
association with the less dense liposome (Fig 23A,B). To enhance detection, the top
fraction was further concentrated by acetone precipitation. SDS-PAGE shows similar
signal intensity, further confirming similar levels of incorporation (Fig. 23C).
As we observed the majority of the rIFITM3 is associated with the
proteoliposome, we sought to estimate how many proteins are present in each
membrane leaflet. Values were calculated based off of reported volumes of
cholesterol96 and PC97, as well as depth of lipid bilayers98. Both starting concentration
and measured phospholipid concentration (0.5 mM) were determined (calculation in
methods section). We estimate a final number of 600-1000 IFITM3 molecules per
liposome (Fig. 24).
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A

B

C

Figure 23. Protein incorporation into the proteoliposome. (A) Histodenz density
gradient (0, 30%, 40%, w/v) was spun down at 50,000 rpm with proteoliposome
containing apoIFITM3 or VAMP2 (protein: lipid 1:1000) and analyzed by SDS PAGE.
(B) Similar gradient analysis was done on all IFITM3 constructs. (C) Improved signal
was obtained by acetone precipitation of 250 μL proteoliposomes, and 150 μL first
fraction of histodenz gradient. Lipid induced mass shift is observed for ML and DL
constructs.
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A

B

IFITM3 Concentration
(Protein: lipid ratio)

IFITM3 Per
LUV at starting
concentration

IFITM3 Per
Bilayer
Leaflet

IFITM3 Per LUV at
final concentration
(0.62 mM)

IFITM3 Per
Bilayer
Leaflet

1 μM (1:1000)

600

300

1000

500

0.2 μM (1:5000)

125

60

200

100

Figure 24. Calculation of IFITM3 concentration per LUV and lipid bilayer leaflet.
(A) Schematic of LUV radius and membrane thickness. Total number of LUV obtained
by dividing total membrane volume (at 1 mM) by bilayer volume (see methods). (B)
Histodenz gradients (Fig. 23) suggest the majority of the protein is incorporated into
LUVs. Dividing the total number of IFITM3 proteins by the number of LUVs yields the
concentration of IFITM3 / LUV.
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Bulk Viral Fusion Assay
The formation of the proteoliposomes is a critical step towards viral fusion
assays, either in bulk solubilized form, or as an intermediate step towards supported
lipid bilayers99. To detect the interaction of the virus and the liposome, previous work in
the

literature

utilizes

self-quenching

fluorophores

incorporated

into

the

viral

envelope27,100,101. Catalyzed by the acidification of the buffer solution, hemi-fusion, or
fusion of the viral envelope with endosome or liposome membrane (reflecting outerleaflet mixing, or fusion pore formation, respectively) leads to diffusion of the
fluorophore, dequenching and increased fluorescent signal (Fig 25).

A

B

Figure 25. DiD labeled IAV enables detection of envelope lipid mixing.
(A) Structure of DiD, a self quenching fluorophores with high affinity for membranes.
(B) Schematic for viral fusion assay. Top: Self quenching DiD increases in fluorescent
intensity upon diffusion into larger membrane area, indicating viral fusion (or hemifusion,
not shown) has occurred. Bottom: bulk fusion assays provide a first step towards testing
whether IFITM3 can independently interfere with the ability of viruses to fuse with target
membranes.
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To support the comparison of our results to previous work in the literature, LUVs
of

similar

lipid

composition102,103

were

used,

with

molar

ratios

of

8:2:0.1

phosphatidylcholine (PC), cholesterol (Chol), hemagglutinin receptor ligand disialoganglioside (GD1a), respectively. As expected, we observed an increase in signal of
DiD dequenching with GD1a (Fig. 26B). Though previous work has indicated that the
presence of cholesterol improves viral fusion90, under our conditions similar levels were
observed when compared with PC and GD1a alone. In contrast, replacing Chol with
phosphatidylethanolamine (PE), a phospholipid of conical shape104 results in a higher
DiD signal, confirming that the virus-liposome fusion properties are influenced by our
choice in lipid composition.
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A

B

Figure 26. Fusion comparison of LUV lipid compositions. Fusion assays were
conducted at 37 °C, and normalized to the max signal of DiD obtained after the addition
of 1% Triton X-100. (A) LUVs were prepared from a combination of PC, Chol, PE, and
GD1a, at identical total concentrations of 1 mM. (B) Same data as A, with PC/PE fusion
data removed for improved resolution.
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Since the temperature might also affect viral fusion and DiD dequenching, similar
fusion conditions were compared at 25 °C and 37 °C (Fig. 27). LUV containing VAMP2,
a SNARE membrane protein105 of similar size to IFITM3 is used as a control for the
impact of background proteins on viral fusion. While trends between the different
liposome conditions were conserved, at 37 °C a stronger signal was observed that
plateaued as early as 15 min into the reaction. In contrast, at 25 °C, DiD dequenching
was continuous, and did not reach a max value even after 90 min. As 37 °C not only
results in faster results that go to completion, but also reflects the physiologically
relevant temperature, all further experiments were conducted under similar conditions.
To show that DiD dequenching was not an artifact of the model, we tested the
functional conditions of the DiD labeled IAV (Fig. 28). IAV fuses with the lipid bilayer of
the late endosome at a pH below 5.5

106

, leading to fusion pore formation and content

release. Fusion should therefore only occur in the presence of an intact viral particle,
LUV, and acidic buffer conditions (pH 5). When comparing IAV alone at pH 5, or IAV
with LUV at pH 7, neither show a significant increase in signal in comparison to IAV with
LUV, at pH 5. This indicates that minimal DiD dequenching occurs due to acidification of
the buffer or spontaneous transfer of DiD from the viral membrane to the LUV. Previous
work by Carr et al.107 showed that IAV fusion can be disrupted by premature unfolding
of the hemagglutinin (HA), caused by either heating at 62 °C for 30 min or premature
acidification at pH 5. Indeed, both conditions disrupted viral fusion in our assay,
supporting our model that DiD dequenching is mediated by HA catalyzed lipid mixing
(fusion/hemifusion).
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A

B

Figure 27. Temperature of IAV fusion affects rate, and signal saturation. LUV and
VAMP2 proteoliposomes were incubated with DiD labeled virus at pH 5, at 25 °C (A)
and 37°C (B). Protein:lipid ratios for all constructs were 1:1000.

60

Figure 28. Viral fusion with LUV is pH, HA dependent. . Minimal signal was observed
under similar conditions at pH 7, or in the absence of LUV. To confirm that HA integrity
was required for fusion, IAV was incubated either at 62 °C for 30 min (HK), or incubated
at pH 5 at 37 °C (preprimed). Both conditions compromise fusion, and DiD
dequenching.

Having characterized the LUV and viral parameters of our model, we proceeded
to fusion assays with LUVs containing rIFITM3. Starting with protein concentrations
similar to other LUV fusion models we titrated the amount of VAMP2 (Fig. 29A) and
apoIFITM3 (Fig. 29B) to determine the dynamic range and saturating concentrations.
Both exhibited a decreasing DiD fluorescence signal at lower protein concentrations,
indicating non-saturating conditions in the protein:lipid range of 1:1000-1:4,000.
We first compared viral fusion with proteoliposomes of VAMP2 and apoIFITM3 at
protein:lipid ratios of 1:1000 to facilitate detection and maximize signal (Fig. 30). Though
our data indicates apoIFITM3 is a non-physiologically occurring phenotype (Fig. 17C) it
provides a first step towards understanding whether S-fatty acylation is critical for
IFITM3 function (in contrast to trafficking or turnover). It also provides a critical control
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for modified lipidated constructs. Viral fusion with LUV containing VAMP2 exhibited DiD
dequenching equivalent to roughly 80% of the empty LUV. Due to high concentrations
of LUV and virus, we hypothesize this is due to background lipid mixing mitigated by
VAMP2 steric hindrance. ApoIFITM3 showed a greater inhibition of DiD dequenching
with max levels reaching approximately 65%, providing first evidence of a direct
interference with viral fusion. Though promising, a helpful control is the loss of function
through the mutation of additional sites. Earlier work by John et al. 10 demonstrated
several point mutations that disrupt the anti-viral activity of IFITM3. Two of these (R85A,
T99A) do not disrupt the addition of PTMs, but rather interfere with the native aminoacid backbone. We therefore generated apoIFITM3-R85A as a control mutant.
Unexpectedly we found it showed similar levels of inhibition to that of the apo-WT. As
this mutation might be non-disruptive under the conditions of the fusion model, we are
continuing our efforts towards functional mutants, with additional point mutants as well
as larger, more disruptive modifications.
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A

B

Figure 29. Titration of VAMP2 and apoIFITM3 confirms dynamic range of
proteoliposome fusion assay. Both VAMP2 (A) and apoIFITM3 (B) were titrated intro
proteoliposomes at the reported ratios, and the DiD signal normalized to the max DiD
value for empty LUV value.
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*

Figure 30. ApoIFITM3 inhibits viral lipid mixing to a greater degree than VAMP2.
Proteoliposomes at a protein:lipid ratio of 1:1000 were incubated with DiD labeled virus
at pH 5, and normalized to the max DiD value of empty LUVs. ApoIFITM3 (yellow) and
R85A (red) show similar levels of activity. Representative of duplicate experiments.
Error bar represents SD.
Having

observed

a

decrease

in

DiD

dequenching

with

apoIFITM3

proteoliposomes, we proceeded to compare IAV fusion with proteoliposomes containing
the various lipidated constructs described in chapter 4 (Fig. 20). To test whether the
constructs showed similar activity levels, we titrated the mono-lipidated constructs over
a protein:lipid range of 1:1000–1:20,000 (Fig. 31). All constructs showed a
concentration dependent increase in inhibition of DiD dequenching, while C105A
appeared to inhibit DiD more effectively than apoIFITM3 (Fig. 31A). To facilitate
experimental design, and inclusion of the double-labeled C72,105 construct (protein
instability resulted in very low protein purification), a protein:lipid ratios of 1:5000 was
chosen for subsequent experiments.
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A

B

Figure 31. All constructs of rIFITM3 inhibit viral lipid mixing. (A) Decreasing ratios
of protein:lipid (higher protein concentration) increase efficacy of inhibition of monolipidated constructs (ML Cys 72, ML Cys 105). Representative of duplicate experiments.
Error bars represent SD. (B) % DiD inhibition (1-max fusion value) at protein:lipid ratio
of 1:5000.

Biological replicates indicate that the apoIFITM3 proteoliposome inhibits DiD
dequenching in comparison to VAMP2 or empty LUVs (Fig. 32). ML-C72 does not alter
IFITM3 inhibition activity, while ML-C105 shows a significant increase of 50% (+/- 29%
SD). Surprisingly the double lipidated construct shows a smaller improvement, inhibiting
DiD dequenching by 30% (+/- 22%- SD). This data indicates that rIFITM3 independently
alters some aspect of the fusion environment that interferes with hemifusion/fusion and
DiD dequenching. Furthermore, lipidated isoforms have Cys-specific affects on rIFITM3
mediated inhibition, with ML-C105 increasing rIFITM3 activity the most. One
interpretation is that the S-fatty acylation of C72, previously shown to be critical for
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IFITM3 anti-viral activity (Fig. 17) plays a role in IFITM3 trafficking and regulation, while
S-fatty acylated C105 augments IFITM3 function. While this model holds promise, more
work is required to correlate the data with in vitro work, such as introduction of rIFITM3
isoforms to tissue culture, or better mimics of the late endosome membrane.

*

Figure 32. Cys specific lipidation of rIFITM3 alters inhibition of DiD dequenching.
Pooled data of four separate fusion assays comparing apoIFITM3 with mono and duallipidated rIFITM3 constructs. Protein:lipid ratio for all experiments 1:5000. Error
represents SD. P<0.05 for unpaired, two-tailed t-test.

To

test

that

the

difference

in

inhibition

between

apoIFITM3

and

ML-105

proteoliposomes is not due to residual mal-palm from the labeling and purification
process, apoIFITM3 was purified a similar manner to ML-105. Comparison of
apoIFITM3 with and without mal-Palm showed identical levels of inhibition of viral fusion
(Fig. 33A). A drawback of the reconstituted bulk fusion assay is the stochastic
incorporation of rIFITM3 into both sides of the liposome membrane. While this insures
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the incorporation of rIFITM3 into the LUV lumen, it also results in virus-facing rIFITM3,
which does not occur under physiological conditions (Fig. 4). To remove outer-leaflet
rIFITM3, we incubated the proteoliposomes for 1 hour with chymotrypsin(Fig. 33B).
While we observed proteolysis of all constructs (Fig. 33C), we did not observe a
change between the extent of inhibition between cleaved and non-cleaved samples.
There are several possible interpretations: (1) the outer leaflet rIFITM3 does not play a
role in viral fusion, with all anti-viral activity exerted by the luminal facing fraction. (2)
The transmembrane domain of the outer-leaflet rIFITM3 contributes to anti-viral activity,
and is retained after chymotrypsin treatment. (3) The cleaved rIFITM3 still adheres to
the LUV membrane and exerts some activity during viral fusion. While this problem can
be better addressed by generating a single-orientation topology, we are unaware of any
techniques that can encapsulate a protein in a liposome, or supported bilayer, without
relying on further proteolysis. Future options for fusion models are discussed in Chapter
6.
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A

B

C

Figure 33. Residual mal-palm, chymotrypsin treatment does not alter proteoliposome fusion properties. (A) Purification of apoIFITM3 under similar mal-palm
labeling conditions as ML-C72/105 does not alter the % inhibition of DiD dequenching in
viral-proteoliposome fusion assays. Protein:lipid 1:5000, (B) Proteoliposomes with or
without chymotrypsin were incubated for 1 hr at 37 °C. After viral fusion assays, the max
DiD value for each condition was normalized to the max value of LUV alone. (C) SDSPAGE of proteoliposomes treated with chymotrypsin. Lower molecular weight bands are
observed for degraded products.
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Methods for Chapter 5:
Generation of proteoliposome through the rapid dilution method:
Modified from Weber et al.
borosilicate

glass

with

86.

PTFE

All chloroform solutions were stored in appropriate
lined

caps

(VWR).

Phosphatidylcholine

and

phosphatidylethanolamine, suspended in chloroform were purchased from Avanti lipids.
10 mg cholesterol (Sigma) was resuspended in 1 mL HPLC grade chloroform (Sigma),
for a final concentration of 25.88 mM.

GD1a (Sigma) was resuspended in a 1:2

methanol:chloroform solution, for a final concentration of 0.544 mM (mw 1882).
For a final total concentration of 1 mM lipid (cholesterol included), appropriate
volumes of each lipid were added to a 13 x 100 mM glass vial, and dried under a gentle
argon stream (a clear reside is observable from at the bottom of the vial). The sample
was then placed under vacuum for at least 2 hours. The dried lipid was resuspended in
1/4 the final total volume by adding Buffer A containing 1% OG, followed by horizontal
shaking (gentle agitation can also be used). Higher resuspension concentrations will
result in an opaque solution. The resuspended lipid was then aliquoted to other glass
vials according to the number of conditions planned. After the addition of protein (the
volume of protein + lipid cannot exceed 1/3 final volume), the lipid-protein solutions
were left at RT for several minutes, then rapidly diluted: on a table top vortex machine
turned to a high setting, the glass vial was pressed down with one hand, while the other
hand added 2-3x the volume of the solution, of buffer A without detergent (depending on
starting volume). This dilutes the OG below the CMC of 0.5% (final 0.25 – 0.3 %),
driving the formation of liposomes.
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To dialyze out the remainder detergent, the entire liposome solution was added
to pre-primed Slide-A-Lyzer MINI Dialysis wells (Thermo, 10k MWCO). Different sized
wells were used depending on the volume of the solution (0.5 mL wells for 4-500 μL
volumes, 3 mL wells for 1-2 mL volumes). The wells were then shaken horizontally at
RT for 1 hr, followed by a buffer exchange and dialysis with horizontal shaking for 6 hr
at 4 °C. Finally, an additional buffer exchange was done, and incubated overnight at 4
°C with horizontal shaking. The next day, the samples were transferred to Eppendorf
tubes with a pipette, and used for the described assays. Samples were kept for a
maximum 1 week at 4 °C.

DiD labeling of IAV
For DiD labeling of IAV, the protocol reported by Desai et al.27 was used with
minor modifications: 200 mg virus (Charles River, catalogue# 10100374, 2 mg/mL,
thawed once and snap frozen in 50 μL aliquots, in liquid nitrogen) was diluted in 300 μL
50 mM sodium bicarbonate buffer (pH 9.0), and incubated with 13.2 μL DiD (Thermo)
for 90 min shaking at RT. During this period, a disposable sephadex column (PD
MiniTrap G-25, GE) was washed 3x with buffer A. To remove excess DiD, the sample
was then added to the column, followed by 100 μL buffer A. The column was then
transferred to a new 15 mL Falcon tub, and eluted with 1 mL of buffer A. The eluted
virus was kept away from light and on ice until use.
For a higher concentration of viral particles, it is possible to pass them through
the G-25 column while centrifuging at 300 x g (see product manual). Though this
removes excess DiD, it does not switch to a more neutral buffer. Care should be given
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to adjusting acidification volumes during fusion experiments. DiD labeled IAV was
usually prepared fresh the day of a fusion experiment, and surplus kept at most 48 hrs
for additional use.

Dynamic Light Scattering (DLS) for measuring proteoliposome diameter.
Proteoliposome size was confirmed using a Wyatt DynaPro DLS Detector II. DLS
is particularly sensitive to background contaminants, so extra care should be given
during sample preparation, such as using Eppendorf tubes with minimal air exposure.
Buffer A prepared with LCMS water (Spectrum Chemical) was filtered with a 0.02 μm
filter (Whatman). Online protocols recommend 0.1 – 0.2 μm filters, though background
signal was observed with our reagents. In 1.5 mL Eppendorf tubes, 200 μL of filtered
buffer A was aliquoted. 2 μL of the sample (1/100) was added to the tube, and inverted
several times to mix. All samples were then centrifuged for 5 min at 20,000 x g at RT,
and three, 60 μL aliquots made in a 384 flat well plate (Greiner). Each sample was
measured 10 times, 10 seconds per measurement.

Phospholipid Quantification.
To determine the total lipid concentration, a total phosphate assay was
generously provided by the Menon Lab at Weill Cornell94. In 13 x 100 mm glass tubes, a
standard was prepared from a 40 mM Na2HPO4 stock solution, of 0, 2, 5, 10, 20, 50, 80
nmol phosphate (Pi), with a final volume of 50 μL. 10 μL of each lipid samples were
then added to additional tubes with 40 μL H2O. 300 μL perchloric acid (HClO4, Sigma)
was added to all conditions, and heated for 1 h at 145 °C. (marbles on the tubes prevent
evaporation). The tubes were then removed from the heating block, 1 mL H2O was
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added, and the solution vortexed briefly to mix. Samples were then left to cool while
preparing 12mg/mL molybdate tetrahydrate (6 mL Sigma) and 50 mg /mL ascorbic acid
(6 mL, MP Biomedicals ). 400 μL of each was then added to each tube, and vortexed to
mix. The tubes were then heated at 100 °C for 10 minutes (make sure the tubes are on
the same heating block, as heating variation will skew results), and cooled again to RT.
200 μL of the standards and samples were then aliquoted in duplicate to a 96 well plate,
and their absorbance measured at 797 nm (minimal color variation will appear in the
lower Pi concentrations and sample).

Theoretical Calculation of rIFITM3 particles / liposome.
For calculating the theoretical number of IFITM3 proteins per LUV, the
membrane thickness was assumed to be 3.7 nm 98., and the volumes of cholesterol96,
and PC97 to be 0.622 nm3 and 1.256 nm3 respectively. Assuming an equal lipid
concentration on each leaflet of the bilayer:
4

1) Volume of lipid bilayer per LUV = 3 𝜋 (𝑅𝐿𝑈𝑉3 - 𝑅𝐿𝑢𝑚𝑒𝑛3 )=

4
3

𝜋 (40nm3 –

(40 (47)nm3 ) = 67,723 nm3
2) Total number of LUV = Total volume of lipids / volume of lipid bilayer
Total volume of 1 mmole lipids = 10−3 ∗ 6.022 ∗ 1023 (0.8 ∗ 1.256 nm3 + 0.2 ∗
0.622 nm3 = 6.8 ∗ 1020 nm3
Total number of LUVs = 6.8 ∗ 1020 nm3 / 67,723 nm3 = 1.005∗ 1016 = 1.667 nmole 
1.667 nM for 1 mM solution of lipids.
3) Number of IFITM3 proteins / LUV = [IFITM3]/ [Concentration LUV]
e.g. 0.2 μM IFITM3 / 1.667 nM LUV = 120 IFITM3 proteins / LUV
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Fusion assay to measure DiD dequenching
For all fusion assays, a digital multi-pipettor was used to enable simultaneous
acidification of multiple conditions. 40 μL of LUV were added in triplicate to a 384 flat
well plate (Greiner) with 20 μL virus. After 5 minute incubation, the solution was acidified
with 4 μL of 50 mM, pH 4 sodium acetate (1/15 of starting volume, final pH 5.0).
Conditions kept at pH 7 were adjusted with 4 μL buffer A. Immediately after acidification,
the plate was measured on a pre-heated BioTek Synergy Neo at 37 °C. Measurements
were taken every 2:30 min, over a period of 40 min, at excitation/emission of 640/670.
After each run, 2 μL of 20% Triton-X 100 was added to all wells to completely solubilize
the DiD and obtain a max signal for reference and normalization.

Data analysis of fusion data.
For data analysis, each time point was normalized to the max DiD signal in the well
obtained after addition of Triton-X-100. Technical replicates were then averaged, and
divided by the max value obtained for LUV alone. This results in a normalized DiD
dequenching curve in reference to LUV max fusion.

Chymotrypsin proteolysis of outer leaflet rIFITM3
Buffer A (negative control) or chymotrypsin (Promega, 25 μg resuspended in 50 μL 50
mM NH4CO3 pH 8) was added to LUV samples at a IFITM3:chymotrypsin ratio of 10:1,
for 1hr at 37 °C. 20 μL was then aliquoted for analysis by SDS-PAGE, and 80 μL used
for the fusion assay.
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Chapter 6: Future directions for rIFITM3 assays
Our proteoliposome-viral fusion assay with rIFITM3 presents the first evidence
that a potential mechanism of IFITM3 viral inhibition is by independently altering the
fusion environment. To investigate the viral fusion mechanism further the current model
needs to be improved, having been originally built off a variety of assays previously
used in the literature (proteoliposome formation86, lipid composition103, viral labeling27).
This setup was initially to our advantage as it allowed us to compare our results to
previous work, and provided a framework to build upon. To determine how IFITM3
might be altering the membrane environment though, we require new assays to detect
content mixing and fusion pore formation, and a better mimic of the late endosome
environment.

Content Mixing Assays:
A facile modification of viral envelopes, the self-quenching properties of DiD
labeling provides a valuable tool for measuring viral fusion. But while DiD can indicate
the initiation point of lipid mixing, it cannot be used to distinguish between hemi-fusion
(the mixing between the outer leaflets of the opposing membranes) and formation of the
complete fusion pore. This is critical in understanding the mechanism of IFITM3, which
has been suggested to interfere with viral fusion and content delivery at the stage of
hemi-fusion27. To be able to distinguish between the two possible stages, future work
will focus on improving our model to detect full fusion pore formation, and pursuant viral
content delivery.
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Measuring content delivery between two populations of liposomes has been
previously reported, using fluorescent dequenching108, or FRET109,110. These assays are
based on encapsulation of two reacting moieties, which is incompatible with our viralLUV model. However, they provide an experimental framework and possible tools for
future use. For viral content labeling, one reported method relies on passive diffusion
across the viral membrane with self-quenching Sulforhodamine B103. While the method
has been used in singe particle measurements, we have not been able to replicate
these results in our bulk fusion assay due to background signal. An additional assay is
the incorporation of fluorescent proteins and probes into the viral nucleocapsid27,111.
Though useful for microscopy-based tracking of content delivery, this approach is
hindered by lacking a gain, or loss of signal.
To address these technical limitations, our future work will focus on exploring two
possible mechanisms for content labeling of viral particles. Both rely on a change in
fluorescent activity (loss or gain), but vary in our incorporation methodology.

1) Incorporation of unnatural amino acid through amber suppression technology.
Amber-codon suppression has proven an invaluable tool for incorporating unnaturally
occurring (synthetic) amino acids (UAA) with functionalized moieties112. This technique
has been used extensively to introduce novel functionalities into proteins, including
photo-activated capture based screens113,114, and post-translational labeling of
IFITM3115. Previous work by other labs has successfully incorporated synthetic amino
acids into viral capsid116,117 and envelope118 proteins, suggesting UAA incorporation
provides a powerful tool for the modification of the influenza nucleocapsid.
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Our first step would be to optimize the incorporation of an unnatural UAA into the
most abundant nucleocapsid protein M1 (which not exposed to the buffer solution). This
UAA could contain either a trans-cyclooctene (TCO) that reacts with several tetrazine
containing fluorophores115, a fluorescent molecule incorporated during viral particle
assembly to be further quenched during exposure to the LUV lumen, or a nucleotide
sequence disrupting FRET based signal as previously reported in the literature 110.
2) Labeling of viral lumen through membrane permeable probes.
An appealing alternative to incorporating the chemical probe during particle assembly
(requiring purification) is the labeling of intact viral particles. This is both more time
effective, and simultaneously applicable to multiple viral samples, enabling strain,
species, and clinical sample comparisons.
A technical difficulty of this model is the necessity of choosing a chemical probe
that can (1) selectively permeate across the viral envelope, and (2) be retained within
the interior. To address this we can utilize a membrane permeable transcycloctene
(TCO) or cyclooctyne derivative (BCN)119, coupled to an amine reactive NHS–Ester120
or photo-coupled diazirine114 for retention within the viral capsid (Fig. 34A). Preliminary
data indicates that a BCN-NHS-Ester can successfully label both envelope proteins as
well as M1 (Fig. 34D). This provides first evidence that the TCO moiety can successfully
transverse the viral membrane, and label capsid proteins.
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A

B

C

D

Figure 34. Labeling of IAV with BCN-NHS-Ester enables fluorescent detection of
IAV capsid proteins by SDS-PAGE. (A) Membrane permeable BCN-NHS probes can
label M1 protein in intact viral particles, and is later labeled with TCO-tagged
fluorophores. (B) List of IAV proteins and their corresponding molecular weight. NS1 is
not present in the viral capsid. (C) Identification of IAV proteins separated by SDSPAGE and stained with coomassie blue (D) Labeling of IAV with BCN-NHS-Ester. Virus
was diluted 1/4 in pH 9 buffer and labeled for 1 hr at RT before excess BCN was
removed by a desalting column, and incubated with 1 mM tetrazine-BODIPY for 15 min.
The sample was then separated by SDS-PAGE and imaged with fluorescence gel
scanning.
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Mimicking Late Endosome Lipid Composition.
Due to the relatively small size of IFITM3, its unknown mechanism, and broad–
spectrum anti-viral activity (Table 1), it is believed IFITM3 inhibits viral fusion by the
alteration of the fusion environment, in particular the biophysical/mechanical properties
of the endosomal membrane. Therefore, the impact of lipid composition choices in our
fusion model must be considered, regardless if done via bulk fusion or supported lipid
bilayer. While

nearly

all

membranes are

comprised

of

approximately

70%

phosphatidylcholine, the remaining lipid composition of lipid species and cholesterol
varies significantly by organelle104. In the literature of bulk liposome fusion assays, a
large fraction of the work is focused on protein-catalyzed membrane fusion with LUVs
mimicking the plasma membrane121 and synaptic vesicles122. For late endosome lipid
composition, there is a paucity of information, the most detailed analysis currently
available having been determined with hamster kidney cells123 (Fig. 35). And while our
understanding of cholesterol trafficking is making strides the field has only a qualitative
understanding that little cholesterol is retained within the limiting membrane during
endosome maturation40,124. Nonetheless, to better emulate late endosome lipid
composition. Our future work will transition away from the literature used ratios of 80%
PC, 20% Chol103. To simplify the complexity of the late endosome, a 3 component
membrane will be used that accounts for main sources of charged lipids, and steric
interactions (Fig. 35B).
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A

32

Lipid
Phosphatidylcholine
Phosphatidylethanolamine
Sphingomyelin
Phosphatidylserine
Cardiolipin
Phosphatidylinositol
Lysobisphosphatidic acid

B

14

p

48.1
19.7
9.2
2.4
0
4.1
15.7

C

50.6
12.4
5.6
5.1
0.1
8.6
14.8

Shape

Charge
Lipid
Phosphatidylcholine
Phosphatidylethanolamine
Phosphatidylserine

Percent total
(molar)
80
20
5

Figure 35. Lipid composition of the late endosome, and proposed mimic.
(A) Kobayashi et al.123, isolated late endosomes from baby hamster kidney (BHK) cells
and determined their composition by TLC and autoradiography. (B) To emulate the late
endosome environment, and reduce the complexity from 7 to 3 different lipids, we
propose using PC, PE, and PS to mimic contributing factors of shape and charge.
Single particle and supported bilayer:
The analysis of viral fusion through bulk assays provides a straightforward
approach to understanding the change in the average total fluorescent signal. But even
should we be able to successfully detect the occurrence of content mixing as described
earlier in the chapter, limitations to the model obscure critical information, such as what
fraction undergoes hemifusion and what fraction complete fusion? Are there changes in
the fusion rates? In the fusion pore size? Furthermore, the smaller size of LUV (80 nm
diameter) results in a surface area of significantly higher membrane curvature in
comparison to that encountered in late endosomes (with a diameter in the range of 300
– 800 nm125).
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To better characterize the fusion event, we intend to conduct single particle
measurements on a supported lipid bilayer, using total internal reflection fluorescence
(TIRF) microscopy126. This model utilizes a single, planer lipid-bilayer assembled from
preformed liposomes, and can be supported by a PEG127,128 or dextran129 cushion,
enabling lipid mobility and space for protein activity. The use of TIRF, with a depth of
field of 60-200 nm126 excludes background signal of viral particles not present at the
lipid membrane, enabling single particle resolution. This technique has been used
extensively to investigate vesicle130, and viral fusion131, and has can resolve the spatial
and temporal progression of single fusion events132,133, providing crucial information as
to the dynamics of lipid mixing, and fusion pore formation (Fig 36).
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Figure 36. Single particle measurements for improved characterization of viral
fusion. Supported lipid bilayers can provide a useful tool for investigating IFITM3
restriction of viral fusion, distinguishing between hemifusion and fusion, as well as
measuring other parameters such as fusion kinetics, IFITM3 colocalization (with proper
labeling), and membrane fluidity.
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Discussion:
Extensive research conducted over the past nine years provides considerable
support to the idea that IFITM3, as well as other members of the IFITM family, plays a
significant role in the first line of defense against most clinically relevant viral pathogens
encountered in the past century. Despite several reports of inflammatory regulation20,42,
the literature indicates that the point of interference occurs prior to viral fusion and
content delivery 27,38,134,135.
As such IFITM3 receives a unique classification: it is part of a group of innate
immunity mechanisms that occurs prior to a viruses’ ability to introduce their varied
methods of virulence or immune evasion136. This distinction increases the importance of
elucidating its mechanism, in particular due to emerging evidence for mutations in
human and avian IAV that can bypass IFITM3 inhibition 18,137, as well as recent reports
that both IFITM2 and IFITM3 play an role in inhibiting HIV infection30,31 (Fig. 37).

Figure 37. IFITMs’ interference with viral fusion and entry is a unique antiviral
mechanism. IFITMs belong to a small group of innate immunity proteins that disrupt
infection prior to entry and the release of viral evasion mechanisms, such as
antibodies138, complement system proteins139, and defensins140. Even more uncommon
is its inhibition at the point of fusion, which we understand to be the only known protein
to directly do so. Viral entry is also inhibited by the upregulation of 25hydroxycholesterol141.
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Earlier work has provided first indicators of possible antiviral mechanisms, with
no definitive results27,34,39. The complexity of the cellular environment prompted us to
approach the question through the use of a recombinant fusion model. We asked
whether we could recapitulate the inhibition of viral fusion in a model system containing
a lipid bilayer with IFITM3. This model system would provide first evidence that perhaps
one of the mechanisms of IFITM3 is by a direct interaction with the fusion environment.
These efforts were enhanced by our development of the mass-shift based Acyl
Peg Exchange (APE) assay, that enables the simultaneous detection of multiple S-fatty
acylation levels of endogenous proteins71. This method addresses a significant limitation
to the field of S-fatty acylation, which until now could only assess total changes in
protein S-fatty acylation, and could not validate the existence the simultaneous S-fatty
acylation events. APE makes it possible to detect physiological S-fatty acylation levels,
as well as compare different tissues, time points, inflammatory conditions etc. The
analysis of endogenous IFITM3 by APE provided several key findings critical to our
future work with recombinant IFITM3; both mouse and human endogenous IFITM3
showed no detectable levels of non-modified (apo) protein (Fig. 16,17), indicating that
all IFITM3 is S-acylated at least once. Furthermore, mouse and human cell lines
showed differing S-fatty acylation levels. While mIFITM3 appeared to have equal levels
of all three S-acylation states, hIFITM3 exhibited only two, with the majority of the
protein being dually-S-acylated (Fig. 17).
Our improved understanding of IFITM3 S-acylation proved critical in generating
recombinant protein, and emulating specific S-acylation states by mal-palm labeling
(Fig. 20). Our purification protocol enables the generation of several mg of protein, does
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not introduce denaturing conditions during enrichment 17,142, is purified from widely
accessible

bacterial

culture,

and

contains

confirmed,

non-reversible

covalent

modifications mimicking S-fatty acylation.
Finally,

the

successful

preparation

and

characterization

of

IFITM3

proteoliposomes paved the way for our first steps towards measuring IFITM3 impact on
the viral fusion. Our observation that in the presence of IFITM3, DiD dequenching is
impaired suggests an IFITM3 mediated decrease in efficiency of viral hemifusion/fusion.
This provides first, preliminary evidence is that IFITM3 can independently exert its antiviral activity, and that the mechanism is either by interacting with the virus directly or
through altering the membrane environment. Broad antiviral activity, and reports in the
literature that hemagglutinin mediated cell-cell fusion can be inhibited by IFITM326,34
provides further support in favor of an alteration to the membrane environs.
With respect to the specific effect IFITM3 is exerting on the membrane environs,
we have yet to apply the necessary assays capable of testing current hypotheses. It is
possible IFITM3 alters the physical properties of the membrane, such as membrane
fluidity, rigidity, or lipid spatial distribution. Alternatively, IFITM3 might directly exert a
steric/entropic inhibition at the site of fusion itself, either in the form of the hemifused
stalk, diaphragm143.
We believe our results justify further work, though the bulk fusion model has
several limitations that would be overcome by an improved experimental setup. Future
experiments will explore single particle tracking - a model that can better mimic the lipid
curvature and composition of the physiological viral-fusion environment, as well as work
to detect content mixing and IFITM3 organization around the fusion locus.
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We believe this data is a promising first step towards understanding the
mechanism of IFITM3. The use of a recombinant system holds promise as a tool that
can rigorously control and monitor the various parameters that will enable us to
elucidate the molecular basis of IFITM3 inhibition in the membrane environment.
Combining this with future structural and in vitro assays, we look forward to expanding
our knowledge if this critical protein.
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